四川大学华西医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma44 篇牵头论文牵头 2 项开放试验
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma71 篇牵头论文牵头 6 项开放试验
- 肝细胞癌Hepatocellular carcinoma392 篇牵头论文牵头 16 项开放试验
- 胃癌Stomach cancer168 篇牵头论文牵头 4 项开放试验
- 肝母细胞瘤Hepatoblastoma4 篇牵头论文
- 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
- 脊索瘤Chordoma3 篇牵头论文
- 骨肉瘤Osteosarcoma36 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour33 篇牵头论文
- 神经母细胞瘤Neuroblastoma5 篇牵头论文牵头 2 项开放试验
- 尤文肉瘤Ewing sarcoma9 篇牵头论文
- 多发性骨髓瘤Multiple myeloma59 篇牵头论文
- B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia1 篇牵头论文
- 再生障碍性贫血Aplastic anaemia4 篇牵头论文
- 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis12 篇牵头论文
- β 地中海贫血Beta thalassaemia2 篇牵头论文
- 血友病 AHaemophilia A4 篇牵头论文
- 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura2 篇牵头论文
- 范可尼贫血Fanconi anaemia1 篇牵头论文
- 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder36 篇牵头论文
- IgG4相关性疾病IgG4-related disease11 篇牵头论文
- 重症肌无力Myasthenia gravis16 篇牵头论文
- 烟雾病Moyamoya disease11 篇牵头论文
- 胆道闭锁Biliary atresia7 篇牵头论文
- 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis22 篇牵头论文
- 大动脉炎Takayasu arteritis3 篇牵头论文
- 肝包虫病Hepatic echinococcosis14 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis31 篇牵头论文
- 肺淋巴管平滑肌瘤病Lymphangioleiomyomatosis2 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis60 篇牵头论文
- 脊髓性肌萎缩症Spinal muscular atrophy1 篇牵头论文
- 法布雷病Fabry disease5 篇牵头论文
- 庞贝病Pompe disease2 篇牵头论文
- 杜氏肌营养不良Duchenne muscular dystrophy2 篇牵头论文
- 白塞病Behçet disease6 篇牵头论文
- Alport 综合征Alport syndrome2 篇牵头论文
- IgA 肾病IgA nephropathy34 篇牵头论文
- 戈谢病Gaucher disease0 篇牵头论文
- 成骨不全症Osteogenesis imperfecta0 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis11 篇牵头论文
- 原发性硬化性胆管炎Primary sclerosing cholangitis3 篇牵头论文
- 先天性膈疝Congenital diaphragmatic hernia5 篇牵头论文
- 先天性巨结肠Hirschsprung disease1 篇牵头论文
- 遗传性大疱性表皮松解症Inherited epidermolysis bullosa4 篇牵头论文
- 遗传性血管性水肿Hereditary angioedema2 篇牵头论文
- 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文
未列出的收录疾病:非典型溶血性尿毒症综合征、肝豆状核变性、尼曼-匹克病 C 型、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 44 篇,占 1.8%。
成都有 5 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下
这家医院参与的开放试验 7
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors
- 分期
- I期
- 开始
- 2026-03
- 登记号
- NCT07625423
年龄 18 岁 至 65 岁(登记的条件)
牵头:四川大学华西医院成都
- 正在招募A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)
- 分期
- I/II期
- 开始
- 2025-06
- 登记号
- NCT07035626
年龄 18 岁 至 80 岁(登记的条件)
牵头:四川大学华西医院成都
- 正在招募A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
- 分期
- II期
- 开始
- 2025-04
- 登记号
- NCT06839066
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心东莞、中山、南宁、广州、成都、杭州、武汉、深圳、福州、赣州、长沙
- 正在招募喉咽清口服液防治鼻咽癌放射性口腔黏膜炎Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
- 分期
- III期
- 开始
- 2025-12
- 登记号
- NCT07311772
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、北京、南宁、常州、广州、成都、昆明、杭州、梧州、汕头、珠海、福州、长沙
- 正在招募40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
- 分期
- III期
- 开始
- 2025-11
- 登记号
- NCT07328854
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心中山、南宁、广州、成都、昆明、杭州、梧州、汕头、珠海、福州、长沙
- 正在招募Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- 分期
- III期
- 开始
- 2024-03
- 登记号
- NCT06239727
年龄 18 岁 至 65 岁(登记的条件)
牵头:中山大学肿瘤防治中心;另有 21 家列出的医院为研究中心东莞、佛山、南京、南宁、南昌、厦门、天津、广州、成都、杭州、武汉、汕头、海口、湛江、福州、西安、贵阳、重庆、长沙
- 正在招募Adebrelimab and Chemoradiotherapy in High-risk LANPC
- 分期
- II期
- 开始
- 2024-07
- 登记号
- NCT06349889
年龄 18 岁 至 65 岁(登记的条件)
牵头:中山大学肿瘤防治中心;另有 3 家列出的医院为研究中心厦门、广州、成都
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。
这些数字背后的记录
牵头的论文44
- Tumor Treatment Response-Guided Adaptive Dose De-escalation/Escalation Strategy for Concurrent Chemoradiation Therapy of Nasopharyngeal Carcinoma.
- Homing Effect Directed Cuprous Delivery Activates Cuproptosis Against Nasopharyngeal Carcinoma and Metastasis.
- Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors.
- Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167).
- Head-to-Head Comparison of 68 Ga-DOTATATE and 18 F-FDG PET in EBV-Positive Nonkeratinizing Nasopharyngeal Carcinoma.
- Neutrophil-to-Lymphocyte Ratio as a Predictor for PD-L1 Inhibitor Treatment in Recurrent or Metastatic Nasopharyngeal Carcinoma.
- Recurrent Patterns in Patients With Nasopharyngeal Caricinoma and Risks Leading to Inaccurate Delineation in Marginal Failure in the Era of Intensity-Modulated Radiotherapy.
- Malignant cell-mediated Treg immune suppression via ICOSLG-ICOS axis in tumor microenvironment relates to nasopharyngeal carcinoma prognosis.
- Effect of enhanced recovery after radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial.
- Immune-related adverse events as prognostic biomarkers in recurrent or metastatic nasopharyngeal carcinoma receiving PD-L1 inhibitor: A post-hoc analysis of the multicenter, single-arm, phase 2 study.
- Unveiling the complex double-edged sword role of exosomes in nasopharyngeal carcinoma.
- Dynamic joint prediction model of severe radiation-induced oral mucositis among nasopharyngeal carcinoma: a prospective longitudinal study.
- Primary and Orthotopic Murine Models of Nasopharyngeal Carcinoma Reveal Molecular Mechanisms Underlying its Malignant Progression.
- Long-term outcomes of metastasis-directed stereotactic body radiation therapy in metastatic nasopharyngeal carcinoma.
- Association between time from diagnosis to treatment and survival of patients with nasopharyngeal carcinoma: A population-based cohort study.
- Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study.
- Risk factors associated with ototoxicity in long-term nasopharyngeal carcinoma survivors.
- Incidence and Risk Factors for Radiotherapy-Induced Oral Mucositis Among Patients With Nasopharyngeal Carcinoma: A Meta-Analysis.
- Epstein-Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma.
- Primary Hepatocellular Carcinoma Revealed on 68 Ga-DOTATATE in a Patient With Nasopharyngeal Carcinoma.
- A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma.
- First-line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta-analysis and cost-effectiveness analysis.
- LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion.
- Screening of core genes and prediction of ceRNA regulation mechanism of circRNAs in nasopharyngeal carcinoma by bioinformatics analysis.
- Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
- Acquired unilateral alopecia after arterial infusion chemotherapy in a recurrent nasopharyngeal carcinoma.
- Quantitative Comparisons of Deep-learning-based and Atlas-based Auto- segmentation of the Intermediate Risk Clinical Target Volume for Nasopharyngeal Carcinoma.
- Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma.
- Local radiotherapy versus nonradiotherapy to distant lesions for metastatic nasopharyngeal carcinoma: Retrospective cohort study.
- The best choice of induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma: Bayesian network meta-analysis.
- Automatic Delineation of Gross Tumor Volume Based on Magnetic Resonance Imaging by Performing a Novel Semisupervised Learning Framework in Nasopharyngeal Carcinoma.
- Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis.
- Computed tomography-based deep-learning prediction of induction chemotherapy treatment response in locally advanced nasopharyngeal carcinoma.
- A nomogram for predicting late radiation-induced xerostomia among locoregionally advanced nasopharyngeal carcinoma in intensity modulated radiation therapy era.
- Comparing the 7th and 8th editions of UICC/AJCC staging system for nasopharyngeal carcinoma in the IMRT era.
- IncRNA ZFAS1 contributes to the radioresistance of nasopharyngeal carcinoma cells by sponging hsa-miR-7-5p to upregulate ENO2.
- Induction chemotherapy followed by intensity-modulated radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma: A retrospective analysis.
- m6A Regulators Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization In Nasopharyngeal Carcinoma.
- Local treatment of metastases plus systemic chemotherapy on overall survival of patients with metastatic nasopharyngeal carcinoma.
- Assessment of different induction chemotherapy regimens in locally advanced nasopharyngeal carcinoma: Meta-analysis.
- Nomograms for predicting survival outcomes in intensity-modulated radiotherapy era of nasopharyngeal carcinoma: A study based on Epstein-Barr virus DNA biological responses.
- Clinical and survival analysis of nasopharyngeal carcinoma with consistently negative Epstein-Barr virus DNA.
- Weight Change Trajectory in Patients With Locally Advanced Nasopharyngeal Carcinoma During the Peri-Radiation Therapy Period.
- A novel dosimetric metrics-based risk model to predict local recurrence in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.
它在 ClinicalTrials.gov 上的全部试验(任何状态)17
- Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors
- A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)
- A Lithium-containing Mouthwash Prevention and Treatment of Oral Mucositis and Dysgeusia in Patients Undergoing Radiotherapy
- Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy
- Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
- 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
- A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
- Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- Adebrelimab and Chemoradiotherapy in High-risk LANPC
- Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
- PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
- The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer
- Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma
- Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
PubMed 以外找到的论文(未计入)52
- 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma
- 728eP Real-world outcomes of a contrast-enhanced ultrasound–integrated follow-up strategy in the management of N3 nasopharyngeal carcinoma after radiotherapy
- A randomized, open-label, multicenter, blank-controlled, phase IV clinical trial of Biyan Qingdu Granula in attenuating acute nose and oral damage in patients undergoing radiotherapy for nasopharyngeal carcinoma.
- Spontaneous resolution of laryngeal contact granuloma following radiotherapy for nasopharyngeal carcinoma: A case report
- Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.
- The value of imaging techniques based on enhanced magnetic resonance imaging in the diagnosis and prediction response of radiotherapy for nasopharyngeal carcinoma
- Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal car
- VER-155008-functionalized Au-polydopamine blackspheres for heat shock proteins 70-targeted near-infrared II region photothermal therapy
- Analysis of proliferating Treg cells as a predictor for immunotherapy response using systemic longitudinal immune profiling: Biomarker analysis of the phase 3 CONTINUUM trial.
- Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.
- Characterizing the impact of sarcopenia on treatment response and survival in previously treated recurrent or metastatic nasopharyngeal carcinoma: Insights from a secondary analysis of the KL-A167 randomized trial.
- Effect of enhanced recovery after radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial.
- Efficacy of nimotuzumab added to concurrent chemoradiotherapy after induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma.
- Elucidating the Immune Microenvironment and Therapeutic Targets in Nasopharyngeal Carcinoma through Bioinformatics
- Evaluation of Adjuvant Chemotherapy after Induction Chemotherapy and Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Patients: A Propensity Score-Matched Analysis
- Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).
- Safety, tolerability, and immunogenicity of WGc-043 in subjects with EBV-positive cancers: Results from an investigator-initiated trial.
- 860MO MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma
- A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors.
- Advancing Delineation of Gross Tumor Volume Based on Magnetic Resonance Imaging by Performing Source-Free Domain Adaptation in Nasopharyngeal Carcinoma
- Automatic Head-and-Neck Tumor Segmentation in MRI via an End-to-End Adversarial Network
- Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
- Long-Term Outcomes of Stereotactic Body Radiation Therapy with or without PD-1 Inhibitors in Metastatic Nasopharyngeal Carcinoma
- Medicine in Nasopharyngeal Carcinoma
- PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM)
- Radiation-induced MDM4 contributes to radioresistant nasopharyngeal carcinoma (NPC) via impaired TP53 transcriptional activity and activated BNIP3-mediated mitophagy
- Research on Longitudinal change trends and influencing factors of eating behaviour in patients with nasopharyngeal carcinoma undergoing radiotherapy
- A phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in patients with advanced solid tumors (TORCH-2).
- Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca
- Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma
- Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 2 of Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma
- Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Mitoxantrone hydrochloride liposome injection in the treatment of recurrent/metastatic head and neck cancers: A multicenter, open-label, single-arm, phase Ⅰb study.
- Multi-transSP: Multimodal Transformer for Survival Prediction of Nasopharyngeal Carcinoma Patients
- The changes of xerostomia and caries risk induced by radiotherapy under the protection of the personalized PMMA oral stents in nasopharyngeal carcinoma patients: a preliminary prospective study
- The global, regional, and national burden of nasopharyngeal carcinoma and its attributable risk factors in 204 countries and territories, 1990–2019
- 436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy
- A Novel Dosimetric Metrics-Based Risk Model to Predict Local Recurrence in Nasopharyngeal Carcinoma Patients Treated With Intensity-Modulated Radiation Therapy
- DA-DSUnet: Dual Attention-based Dense SU-net for automatic head-and-neck tumor segmentation in MRI images
- Efficient Semi-supervised Gross Target Volume of Nasopharyngeal Carcinoma Segmentation via Uncertainty Rectified Pyramid Consistency
- JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
- Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase
- Malposition of a Nasogastric Feeding Tube Into the Right Pleural Cavity of a Nasopharyngeal Carcinoma Patient After Radiotherapy and Chemotherapy: A Case Report
- Semi-supervised NPC segmentation with uncertainty and attention guided consistency
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 71 篇,占 2.4%。
成都有 3 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
这家医院参与的开放试验 9
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC
- 分期
- II期
- 开始
- 2026-04
- 登记号
- NCT07519486
年龄 18 岁 至 80 岁(登记的条件)
牵头:四川大学华西医院成都
- 正在招募A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
- 分期
- I/II期
- 开始
- 2025-09
- 登记号
- NCT06753747
年龄 18 岁 至 75 岁(登记的条件)
牵头:四川大学华西医院成都
- 正在招募Oncolytic Virus in Esophageal Squamous Cell Carcinoma
- 分期
- I/II期
- 开始
- 2025-08
- 登记号
- NCT07061704
年龄 18 岁 至 80 岁(登记的条件)
牵头:四川大学华西医院成都
- 正在招募Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
- 分期
- II期
- 开始
- 2024-06
- 登记号
- NCT06446726
年龄 18 岁 至 75 岁(登记的条件)
牵头:四川大学华西医院成都
- 正在招募Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
- 分期
- II期
- 开始
- 2024-10
- 登记号
- NCT06675201
年龄 18 岁 至 80 岁(登记的条件)
牵头:四川大学华西医院成都
- 即将招募Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
- 分期
- I期
- 开始
- 2025-09
- 登记号
- NCT07154108
年龄 18 岁 至 75 岁(登记的条件)
牵头:四川大学华西医院成都
- 正在招募SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- 分期
- II期
- 开始
- 2026-08
- 登记号
- NCT07700667
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心南京、南宁、南昌、哈尔滨、天津、太原、成都、昆明、汕头、沈阳、洛阳、石家庄、福州、西安、郑州、长春
- 正在招募A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- 分期
- III期
- 开始
- 2025-03
- 登记号
- NCT06644781
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春
- 即将招募Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
- 分期
- 未注明
- 开始
- 2026-09
- 登记号
- NCT07769658
年龄 18 岁 至 80 岁(登记的条件)
牵头:郑州大学第一附属医院;另有 5 家列出的医院为研究中心上海、天津、广州、成都、昆明、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文71
- Preoperative Physiological Reserve and Pathological Response as Independent Predictors of Survival in Esophageal Squamous Cell Carcinoma after Neoadjuvant Therapy.
- Targeting TFAP2β condensation suppresses the development of esophageal squamous cell carcinoma.
- 68Ga-FAPI and 18F-FDG PET/CT for predicting pathologic response and progression-free survival in locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
- Efficacy of adjuvant immunotherapy and immunochemotherapy in esophageal squamous cell carcinoma: A retrospective cohort study.
- Does Pseudo-Lymph Node Skip Metastasis After Neoadjuvant Therapy Affect Esophageal Squamous Cell Carcinoma Outcomes? A Multicenter Study.
- Artificial intelligence in endoscopic diagnosis of esophageal squamous cell carcinoma and precancerous lesions.
- The Efficacy of Time Interval Between Neoadjuvant Chemoimmunotherapy and Surgery on Outcomes in Oesophageal Squamous Cell Carcinoma.
- Expression and prognostic value of estrogen-related receptor β alternative splicing isoforms in esophageal squamous cell carcinoma.
- Real-world survival benefit of adding immunotherapy to chemotherapy in esophageal cancer: A large SEER-based analysis.
- Personalized neoantigen DC vaccine combined with camrelizumab following definitive therapy in locally advanced unresectable esophageal squamous cell carcinoma (CHANT-241): protocol for a randomized controlled trial.
- A circRNA promotes esophageal squamous cell carcinoma progression by inhibiting TRIM25-mediated degradation of IGF2BP family members.
- Spatial transcriptomic analysis of tumor microenvironment in esophageal squamous cell carcinoma with HIV infection.
- Risk factors and prognosis of postoperative early relapse after neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a retrospective study.
- Esophageal squamous cell carcinoma with EP300 mutations displays distinct genetic characteristics relevant to neoadjuvant chemoradiotherapy.
- Increased resected lymph node stations improved survival of esophageal squamous cell carcinoma.
- Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial.
- Radiotherapy and chemoradiotherapy for postoperative recurrence in patients with esophageal squamous cell carcinoma.
- Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
- A platform of functional studies of ESCC-associated gene mutations identifies the roles of TGFBR2 in ESCC progression and metastasis.
- Mapping of lymph node metastasis from esophageal squamous cell carcinoma after neoadjuvant treatment: a prospective analysis from a high-volume institution in China.
- A novel tumor staging system incorporating cN status for stratifying early stage esophageal squamous cell carcinoma patients after trimodal therapy.
- Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions.
- A machine learning radiomics based on enhanced computed tomography to predict neoadjuvant immunotherapy for resectable esophageal squamous cell carcinoma.
- Does increasing the number of resected lymph nodes really improve the prognosis of patients with esophageal squamous cell carcinoma?
- Impact of deep muscle invasion on nodal status and survival in patients with pT2 esophageal squamous cancer.
- Impact of change in the Naples prognostic score after neoadjuvant chemoradiotherapy on survival in esophageal squamous cell carcinoma patients.
- Prognostic factors for patients with pathologic T1-T2N+ esophageal squamous cell carcinoma: A retrospective study with external validation.
- Correlation between tumor budding and the long-term follow-up outcomes after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma.
- Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions - Authors' reply.
- Effect of an artificial intelligence-assisted system on endoscopic diagnosis of superficial oesophageal squamous cell carcinoma and precancerous lesions: a multicentre, tandem, double-blind, randomised controlled trial.
- Identifying TOPK and Hypoxia Hallmarks in Esophageal Tumors for Photodynamic/Chemo/Immunotherapy and Liver Metastasis Inhibition with Nanocarriers.
- Longer Time Interval from Neoadjuvant Chemoradiation to Surgery is Associated with Poor Survival for Patients Without Clinical Complete Response in Oesophageal Cancer.
- ASO Author Reflections: Timing of Oesophagectomy After Neoadjuvant Chemoradiotherapy for Locally Advanced Oesophageal Cancer.
- Esophageal squamous cell carcinoma presenting as a submucosal tumor.
- Pararespiratory and paradigestive lymph node metastases in esophageal squamous cell carcinoma: predicting survival and refining the N staging system.
- ERK inhibitor: A candidate enhancing therapeutic effects of conventional chemo-radiotherapy in esophageal squamous cell carcinoma.
- Identification and Validation of Co-Expressed Immune-Related Gene Signature Affecting the Pattern of Immune Infiltrating in Esophageal Cancer.
- Combine radiotherapy and immunotherapy in esophageal squamous cell carcinoma.
- Artificial intelligence for detecting and delineating a small flat-type early esophageal squamous cell carcinoma under multimodal imaging.
- MTHFD1L confers a poor prognosis and malignant phenotype in esophageal squamous cell carcinoma by activating the ERK5 signaling pathway.
- Artificial intelligence for detecting and delineating the extent of superficial esophageal squamous cell carcinoma and precancerous lesions under narrow-band imaging (with video).
- The investigation of volatile organic compounds in diagnosing (early) esophageal squamous cell carcinoma and gastric adenocarcinoma.
- Comprehensive landscape of resistance mechanisms for neoadjuvant therapy in esophageal squamous cell carcinoma by single-cell transcriptomics.
- Development and validation of a model to determine the risk of esophageal strictures after endoscopic submucosal dissection for esophageal neoplasms.
- Lymphovascular and Perineural Invasion After Neoadjuvant Therapy in Esophageal Squamous Carcinoma.
- Risk factors and a predictive nomogram for lymph node metastasis in superficial esophageal squamous cell carcinoma.
- Association of the Modified Albumin-Bilirubin Grade with Survival Outcomes in Esophageal Squamous Cell Carcinoma.
- Overexpressed COL3A1 has prognostic value in human esophageal squamous cell carcinoma and promotes the aggressiveness of esophageal squamous cell carcinoma by activating the NF-κB pathway.
- Artificial Intelligence for Detecting and Delineating Margins of Early ESCC Under WLI Endoscopy.
- The comparisons of neoadjuvant chemoimmunotherapy versus chemoradiotherapy for oesophageal squamous cancer.
- Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives.
- Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma.
- Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
- Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma.
- A Commentary on "The minimum number of examined lymph nodes for accurate nodal staging and optimal survival of stage T1-2 esophageal squamous cell carcinoma: A retrospective multicenter cohort with SEER database validation" [Int. J. Surg. (
- The minimum number of examined lymph nodes for accurate nodal staging and optimal survival of stage T1-2 esophageal squamous cell carcinoma: A retrospective multicenter cohort with SEER database validation.
- Artificial intelligence for detecting superficial esophageal squamous cell carcinoma under multiple endoscopic imaging modalities: A multicenter study.
- Characterization of distinct circular RNA signatures in solid tumors.
- Identifying a confused cell identity for esophageal squamous cell carcinoma.
- Raman spectroscopy and machine learning for the classification of esophageal squamous carcinoma.
- Artificial intelligence for diagnosing microvessels of precancerous lesions and superficial esophageal squamous cell carcinomas: a multicenter study.
- Prognostic Role of Nodal Skip Metastasis in Thoracic Esophageal Squamous Cell Carcinoma: A Large-Scale Multicenter Study.
- ASO Author Reflections: Nodal Skip Metastasis Is Associated with Survival Benefit in Thoracic Esophageal Squamous Cell Carcinoma.
- The interaction of TEA domain transcription factor 4 (TEAD4) and Yes-associated protein 1 (YAP1) promoted the malignant process mediated by serum/glucocorticoid regulated kinase 1 (SGK1).
- PIWIL2 interacting with IKK to regulate autophagy and apoptosis in esophageal squamous cell carcinoma.
- Fc fragment of immunoglobulin G receptor IIa (FCGR2A) as a new potential prognostic biomarker of esophageal squamous cell carcinoma.
- Identification of Epithelial-Mesenchymal Transition- (EMT-) Related LncRNA for Prognostic Prediction and Risk Stratification in Esophageal Squamous Cell Carcinoma.
- Combination of Modified Free Anterolateral Thigh Skin-Fascia Flap and Pedicled Thoracoacromial Artery Perforator Flap for Entire Circumferential Pharyngoesophageal Defect and External Neck Skin Defect Reconstructions.
- Role of nodal skip metastasis in patients with mid-thoracic oesophageal squamous cell carcinoma: a propensity score matching study.
- Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma.
- Surgical Treatment for an Esophageal Carcinoma With a Pancreatic Pseudocyst.
它在 ClinicalTrials.gov 上的全部试验(任何状态)27
- A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
- Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
- Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas
- Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC
- Oncolytic Virus in Esophageal Squamous Cell Carcinoma
- Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
- Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
- Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
- Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis
- Survival Prediction After Neoadjuvant Chemoimmunotherapy and Esophagectomy for Esophageal Squamous Cell Carcinoma
- Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer
- Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC
- A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC
- SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
- A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors
- A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
- A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors
- A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
- A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
- A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma
PubMed 以外找到的论文(未计入)62
- 013. VALUE OF COMBINING THE NUMBER OF LYMPH NODE STATIONS AND TUMOR REGRESSION GRADE IN THE NEOADJUVANT TREATMENT OF ESOPHAGEAL CANCER
- 035. THE EFFECT OF SURGICAL INTERVAL POST-NEOADJUVANT CHEMOIMMUNOTHERAPY ON LONG-TERM OUTCOMES IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 089. SPECTRAL CT-BASED NON-INVASIVE PREDICTION OF NEOADJUVANT CHEMOTHERAPY RESPONSE AND POSTOPERATIVE LYMPH NODE METASTASIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 097. TARGETING FUSOBACTERIUM NUCLEATUM WITH MRNA-LNP VACCINES RESTORES PD-1 SENSITIVITY AND REPROGRAMS THE TUMOR MICROENVIRONMENT IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 121. EFFICIENCY INDEX OF LYMPH NODE DISSECTION FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER NEOADJUVANT THERAPY
- 138. MULTI-CENTER CLINICAL ANALYSIS AND SINGLE-CELL SEQUENCING INSIGHTS INTO THE DEVELOPMENTAL MECHANISMS OF SYNCHRONOUS MULTIPLE PRIMARY ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 142. PREDICTIVE ROLE OF CTDNA IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA RECEIVING NEOADJUVANT IMMUNOTHERAPY AND CHEMOTHERAPY: A PROSPECTIVE COHORT STUDY
- 143. LONG-TERM DYSPHAGIA AND REGURGITATION IN 10-YEAR ESOPHAGEAL SQUAMOUS CELL CARCINOMA SURVIVORS: PREVALENCE, CORRELATES, AND PREDICTIVE MODELS IN A MULTI-CENTER COHORT
- 149. DOES PSEUDO-LYMPH NODE SKIP METASTASIS AFTER NEOADJUVANT THERAPY AFFECT ESOPHAGEAL SQUAMOUS CELL CARCINOMA OUTCOMES?—A MULTICENTER STUDY
- 206. ENO1 LACTYLATION AS A PROMISING PREDICTIVE BIOMARKER AND THERAPEUTIC TARGET FOR ESCC METASTASIS
- 207. LOW-DOSE INVOLVED-FIELD RT, PLUS IMMUNOCHEMOTHERAPY SHOWED EXCELLENT EFFICACY AND LOW TOXICITIES IN UNRESECTABLE LA-ESCC: A PROSPECTIVE PHASE II STUDY
- 279. GENOMIC COPY NUMBER IDENTIFIES DRIVER MUTATIONS OF METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 321. CTHRC1-MEDIATED MEGAKARYOCYTE/PLATELET INFILTRATION IN THE TUMOR MICROENVIRONMENT PROMOTES IMMUNOTHERAPY RESISTANCE IN ESCC
- 329. COMPARISON OF TWO DIFFERENT END-TO-END HAND-SEWN ANASTOMOSES IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A RETROSPECTIVE STUDY
- 387. RNA M6A METHYLATION PROMOTES TUMOR DEVELOPMENT AND WASF3 TRANSLATION IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- A phase I dose-escalation study to evaluate safety and feasibility of neoadjuvant camrelizumab with palbociclib for the treatment of resectable esophageal squamous cell carcinoma (ESCC).
- Conversion Surgery for cT4b Esophageal Squamous Cell Carcinoma
- Predictive factors for treatment response to neoadjuvant PD-1 inhibitor and chemotherapy in locally advanced esophageal squamous cell carcinoma
- Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis
- Uniportal versus multiportal video-assisted thoracic surgery for esophageal cancer: a randomized clinical trial
- 1426P BL-B01D1, an EGFR x her3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)
- 235. A NOVEL TUMOR STAGING SYSTEM INCORPORATING CN STATUS FOR STRATIFYING EARLY STAGE ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS AFTER TRIMODAL THERAPY
- 236. THE ROLE OF ADJUVANT THERAPY FOLLOWING NEOADJUVANT CHEMORADIOTHERAPY AND ESOPHAGECTOMY IN ESOPHAGEAL CANCER
- 240. CACHEXIA INDEX AS A POTENTIAL BIOMARKER FOR SENSITIVITY OF NEOADJUVANT THERAPY AND PROGNOSIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 384. NEOADJUVANT ANLOTINIB COMBINED WITH PENPULIMAB FOR RESECTABLE LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC): A PROSPECTIVE, SINGLE-ARM, PHASE II TRIAL
- 398. DYSPHAGIA OR REGURGITATION AND ITS CORRELATES AMONG UP TO 10-YEAR ESOPHAGEAL SQUAMOUS CELL CARCINOMA SURVIVORS
- 424. EFFECT OF GUT MICROBIOTA ON THE RESPONSE TO NEOADJUVANT IMMUNOTHERAPY COMBINED WITH CHEMOTHERAPY IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 436. IDENTIFICATION OF M6A-RELATED SIGNATURE GENES IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA BY MACHINE LEARNING METHOD
- 439. INTEGRATION OF SCRNA-SEQ AND BULK RNA-SEQ TO VALIDATE A PROGNOSTIC ASSOCIATED SIGNATURE IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 626. DO CALCIUM CHANNEL BLOCKERS AFFECT CLINICAL OUTCOMES IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA WITH HYPERTENSION? A MULTICENTER RETROSPECTIVE STUDY
- 798. FEASIBILITY AND EFFICACY OF CISPLATIN, PACLITAXEL AND IMMUNE CHECKPOINT INHIBITORS AS CONVERSION THERAPY FOR LOCOREGIONALLY UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- A Phase II Clinical Trial of Sintilimab Combined with Lower Dose Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
- Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.
- Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II trial.
- Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Updated data from a prospective, phase II trial.
- 14. IMPACTS OF ADDITIONAL CYCLES OF NEOADJUVANT IMMUNOCHEMOTHERAPY ON ESOPHAGECTOMY IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 145P Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
- 186. PROGNOSTIC ROLE OF NODAL SKIP METASTASIS IN THORACIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A LARGE-SCALE MULTICENTER STUDY
- 187. PROGNOSTIC IMPACT OF LYMPH NODE HARVEST FOR PATIENTS WITH NODE-NEGATIVE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A LARGE-SCALE MULTICENTER STUDY
- 188. VITAMIN D RECEPTOR INDUCES OXIDATIVE STRESS TO PROMOTE ESOPHAGEAL SQUAMOUS CELL CARCINOMA PROLIFERATION VIA THE P53 SIGNALING PATHWAY
- 189. IDENTIFICATION OF M6A-RELATED SIGNATURE GENES IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA BY MACHINE LEARNING METHOD
- 24. A NOVEL TUMOR STAGING SYSTEM INCORPORATING CN STATUS FOR STRATIFYING EARLY STAGE ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS AFTER TRIMODAL THERAPY
- 401. THE ADJUVANT IMMUNOTHERAPY COMBINATIONS FOLLOWING ESOPHAGECTOMY FOR RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WITH NEOADJUVANT THERAPY
- 402. LYMPH NODE METASTASIS MAPPING IN T1–2 ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 430. MAPPING OF LYMPH NODE METASTASIS FROM ESCC AFTER NEOADJUVANT TREATMENT: A PROSPECTIVE ANALYSIS FROM A HIGH-VOLUME INSTITUTION IN CHINA
- 444. SHOULD T2 ESOPHAGEAL SQUAMOUS CELL CARCINOMA BE SUBCLASSIFIED WITH RESPECT TO LYMPH NODE INVOLVEMENT AND SURVIVAL?
- 485. MATTHEW EFFECT OF NEOADJUVANT THERAPY IN ESOPHAGEAL CANCER
- Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway
- P-60 Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: A single-arm phase II clinical trial
- 137. THE COMPARISON OF SHORT-TERM OUTCOMES BETWEEN NEOADJUVANT CHEMOTHERAPY COMBINED WITH IMMUNOTHERAPY AND NEOADJUVANT CHEMORADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CANCER
- 153. APPLICATION OF RAMAN SPECTROSCOPY AND MACHINE LEARNING IN THE CLASSIFICATION OF ESOPHAGEAL SQUAMOUS CARCINOMA
- 231. A NOMOGRAM BASED ON BODY MASS INDEX CHANGES TO PREDICT PROGNOSIS AFTER CURATIVE RESECTION OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 241. A VALIDATED NOMOGRAM PREDICTING LYMPH NODE METASTASIS OF T2N0 ESOPHAGEAL SQUAMOUS CELL CARCINOMA FOR CLINICAL DECISION-MAKING
- Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma
- Additional file 1 of PABPC1-induced stabilization of IFI27 mRNA promotes angiogenesis and malignant progression in esophageal squamous cell carcinoma through exosomal miRNA-21-5p
- Additional file 2 of Serum proteomics unveil characteristic protein diagnostic biomarkers and signaling pathways in patients with esophageal squamous cell carcinoma
- Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma
- MiR-4739 inhibits the malignant behavior of esophageal squamous cell carcinoma cells via the homeobox C10/vascular endothelial growth factor A/phosphatidylinositol 3-kinase/AKT pathway
- 155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm pha
- 820 EFFICACY AND SAFETY OF ENDOSCOPIC SUBMUCOSAL DISSECTION FOR SUPERFICIAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA AND PRECANCEROUS LESIONS
- MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel
- Ultrasound-Stimulated Microbubbles Inhibit Aggressive Phenotypes and Promotes Radiosensitivity of esophageal squamous cell carcinoma
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 392 篇,占 2.6%。
成都有 5 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
这家医院参与的开放试验 23
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC
- 分期
- 早期I期
- 开始
- 2026-01
- 登记号
- NCT07295262
年龄 18 岁 至 75 岁(登记的条件)
牵头:四川大学华西医院成都
- 正在招募Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection
- 分期
- 未注明
- 开始
- 2026-03
- 登记号
- NCT07295275
年龄 18 岁 至 80 岁(登记的条件)
牵头:四川大学华西医院;另有 2 家列出的医院为研究中心北京、徐州、成都
- 正在招募Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection
- 分期
- 未注明
- 开始
- 2026-01
- 登记号
- NCT07295340
年龄 18 岁 至 80 岁(登记的条件)
牵头:四川大学华西医院成都
- 正在招募Surgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma
- 分期
- 未注明
- 开始
- 2026-03
- 登记号
- NCT07410715
年龄 18 岁 至 80 岁(登记的条件)
牵头:四川大学华西医院成都
- 正在招募PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
- 分期
- II期
- 开始
- 2026-04
- 登记号
- NCT07463248
年龄 18 岁 至 75 岁(登记的条件)
牵头:四川大学华西医院成都
- 正在招募A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
- 分期
- I/II期
- 开始
- 2026-02
- 登记号
- NCT07482059
年龄 18 岁 至 80 岁(登记的条件)
牵头:四川大学华西医院成都
- 正在招募Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma
- 分期
- 未注明
- 开始
- 2025-04
- 登记号
- NCT06950827
年龄 18 岁 至 未注明(登记的条件)
牵头:四川大学华西医院成都
- 正在招募PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
- 分期
- I期
- 开始
- 2025-10
- 登记号
- NCT07053072
年龄 18 岁 至 70 岁(登记的条件)
牵头:四川大学华西医院成都
- 正在招募Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma
- 分期
- I期
- 开始
- 2025-08
- 登记号
- NCT07077356
年龄 18 岁 至 未注明(登记的条件)
牵头:四川大学华西医院成都
- 正在招募A Study of GV20-0251 in Advanced or Refractory Solid Tumors
- 分期
- I期
- 开始
- 2025-09
- 登记号
- NCT07106827
年龄 18 岁 至 未注明(登记的条件)
牵头:四川大学华西医院成都
- 正在招募PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
- 分期
- II期
- 开始
- 2024-10
- 登记号
- NCT06742424
年龄 18 岁 至 75 岁(登记的条件)
牵头:四川大学华西医院成都
- 正在招募Application of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection
- 分期
- 不分期
- 开始
- 2023-12
- 登记号
- NCT06219096
年龄 18 岁 至 75 岁(登记的条件)
牵头:四川大学华西医院成都
- 即将招募Integration of Imaging, Molecular, Pathological, and Clinical Outcome Data in Hepatocellular Carcinoma.
- 分期
- 未注明
- 开始
- 2027-01
- 登记号
- NCT07912853
年龄 18 岁 至 未注明(登记的条件)
牵头:四川大学华西医院成都
- 即将招募Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC
- 分期
- 不分期
- 开始
- 2026-04
- 登记号
- NCT07480382
年龄 18 岁 至 80 岁(登记的条件)
牵头:四川大学华西医院成都
- 即将招募YMN-A02 for Advanced Primary Hepatocellular Carcinoma.
- 分期
- I期
- 开始
- 2026-07
- 登记号
- NCT07580261
年龄 18 岁 至 70 岁(登记的条件)
牵头:四川大学华西医院成都
- 即将招募Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
- 分期
- 不分期
- 开始
- 2026-12
- 登记号
- NCT07866612
年龄 18 岁 至 80 岁(登记的条件)
牵头:四川大学华西医院;另有 8 家列出的医院为研究中心上海、北京、南京、广州、成都、福州、重庆
- 正在招募Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- 分期
- 未注明
- 开始
- 2025-09
- 登记号
- NCT07170345
年龄 18 岁 至 18 岁(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南宁、广州、成都、沈阳、温州、珠海、福州、郑州
- 正在招募ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- 分期
- II期
- 开始
- 2025-06
- 登记号
- NCT07327034
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙
- 正在招募Phase 2 Study of WGI-0301 for Advanced HCC
- 分期
- II期
- 开始
- 2024-07
- 登记号
- NCT06309485
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 7 家列出的医院为研究中心南昌、哈尔滨、成都、杭州、武汉、长沙
- 正在招募Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- 分期
- III期
- 开始
- 2023-05
- 登记号
- NCT05862337
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙
- 正在招募CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
- 分期
- I期
- 开始
- 2023-10
- 登记号
- NCT06560827
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、武汉、沈阳、福州、郑州、长沙
- 正在招募Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
- 分期
- I/II期
- 开始
- 2022-12
- 登记号
- NCT05652920
年龄 18 岁 至 70 岁(登记的条件)
牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、北京、成都、杭州、长春、长沙
- 即将招募Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
- 分期
- III期
- 开始
- 2026-01
- 登记号
- NCT07356037
年龄 18 岁 至 85 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心成都
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文392
- Radiofrequency ablation is safe in patients with hepatocellular carcinoma and thrombocytopenia.
- Imaging for molecular and pathological subtyping of hepatocellular carcinoma-a critical appraisal and future directions.
- 3D fractal dimension analysis of CT imaging for microvascular invasion prediction in hepatocellular carcinoma.
- Laparoscopic liver resection is superior to open liver resection for hepatocellular carcinoma patients with BCLC stage 0-A hepatocellular carcinoma and portal hypertension.
- Efficacy and safety of immune checkpoint inhibitors in hepatocellular carcinoma: a comprehensive umbrella review of meta-analyses.
- Ultrasound shear wave viscoelastic imaging combined with shear wave elastography for characterization of focal liver lesions.
- Emerging Role of MRI-Based Artificial Intelligence in Individualized Treatment Strategies for Hepatocellular Carcinoma: A Narrative Review.
- Multicenter study on right Glissonean pedicle management in laparoscopic right hepatectomy: main trunk vs. sectoral pedicle transection approaches.
- Laparoscopic versus open hepatectomy in hepatocellular carcinoma patients with high-risk pathological features: a multicenter propensity score-matched study.
- Impact of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease on Hepatocellular Carcinoma Incidence and Long-Term Prognosis Post-Liver Resection: A Systematic Review and Meta-Analysis.
- Perfluorohexane nanodroplet-assisted mechanical high intensity focused ultrasound cavitation: A strategy for hepatocellular carcinoma treatment.
- Association of the Number of Concurrent Metabolic Syndrome Risk Factors with Textbook Outcomes Following Liver Resection for Patients with Hepatocellular Carcinoma: A Multicenter Study.
- Prognostic Impact of the Pathologic Response of Patients with Hepatocellular Carcinoma After Preoperative Treatments.
- Development and validation of a small-sample machine learning model to predict 5-year overall survival in patients with hepatocellular carcinoma.
- Low preoperative serum creatinine levels are associated with poor prognosis in patients with hepatocellular carcinoma after liver resection: a multicenter study.
- Nomogram for predicting early cancer-related death due to recurrence after liver resection in hepatocellular carcinoma patients with Barcelona Clinic Liver Cancer (BCLC) stage B/C: a multicenter study.
- Discovery of targeting USP10-mediated proline metabolism arrangement to inhibit hepatocellular carcinoma progression.
- Histone lactylation facilitates MCM7 expression to maintain stemness and radio-resistance in hepatocellular carcinoma.
- Utilizing liquid-liquid biopolymer regulators to predict the prognosis and drug sensitivity of hepatocellular carcinoma.
- Radiotherapy enhances triple therapy for conversion and survival in patients with unresectable hepatocellular carcinoma with portal vein tumor thrombus.
- Textbook outcome and survival following laparoscopic versus open right hemihepatectomy for hepatocellular carcinoma: A propensity score-matched study.
- Performance of simultaneous multislice diffusion-weighted imaging using monoexponential, intravoxel incoherent motion, and diffusion kurtosis models: assessment of microvascular invasion and histologic grade in hepatocellular carcinoma.
- Recent Advancements in Known and Emerging Risk Factors of Hepatocellular Carcinoma.
- Preoperative Hepatic Augmentation Versus Transarterial Chemoembolization for Hepatocellular Carcinoma With Insufficient Remnant Liver Volume: A Systematic Review and Meta-Analysis.
- Targeting p38γ synergistically enhances sorafenib-induced cytotoxicity in hepatocellular carcinoma.
- Halting hepatocellular carcinoma: Identifying intercellular crosstalk in HBV-driven disease.
- circCEP70 encoded protein inhibits the progression of hepatocellular carcinoma.
- EIF2B4 promotes hepatocellular carcinoma progression and immune evasion by driving STAT3 translation via a GEF-dependent mechanism.
- Tenofovir vs Entecavir on the Prognosis of Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma After Liver Resection: The Role of HBsAg Levels.
- Acute cutaneous adverse drug reactions in hepatocellular carcinoma patients undergoing combined targeted and immunotherapy: unraveling the impact of dosage and interval.
- Long-Term Outcome of Repeat Resection versus Radiofrequency Ablation for Intrahepatic Recurrence after Curative Resection of Hepatocellular Carcinoma Initially within Barcelona Clinic Liver Cancer Staging System 0-A Stages: A Multicenter St
- Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study.
- Imaging-based prediction of early recurrence and neoadjuvant therapy outcomes for resectable beyond Milan HCC.
- Validation of the Iwate scoring system for the stratification of laparoscopic liver resections: An international multicenter study.
- MRI-based prediction of microvascular invasion/high tumor grade and adjuvant therapy benefit for solitary HCC ≤ 5 cm: a multicenter cohort study.
- MRI-based prediction of the need for wide resection margins in patients with single hepatocellular carcinoma.
- Deep learning-based 3D quantitative total tumor burden predicts early recurrence of BCLC A and B HCC after resection.
- Temporal evolution of the LI-RADS radiation treatment response assessment on multiphase CT/MRI in patients undergoing selective internal radiation therapy for hepatocellular carcinoma.
- Preoperative prediction of early recurrence in hepatocellular carcinoma using simultaneous multislice diffusion kurtosis imaging.
- ANK3 Is Regulated by Recursive Splicing and Inhibits Hepatocellular Carcinoma Metastasis by Inhibiting E-Cadherin Protein Degradation.
- The role of bile acid metabolism-related genes in prognosis assessment of hepatocellular carcinoma and identification of NPC1 as a biomarker.
- Tumor regression grade predicts recurrence-free survival in intermediate-advanced hepatocellular carcinoma after conversion therapy.
- Case Report: Abscopal effect in a patient with refractory metastatic hepatocellular carcinoma treated with stereotactic body radiotherapy and PD-1 inhibitor.
- Preoperative assessment of liver regeneration using T1 mapping and the functional liver imaging score derived from Gd-EOB-DTPA-enhanced magnetic resonance for patient with hepatocellular carcinoma after hepatectomy.
- Radiomics-based biomarker for PD-1 status and prognosis analysis in patients with HCC.
- The XIAP inhibitor AZD5582 improves the treatment effect of microwave ablation on hepatocellular carcinoma.
- Nivolumab plus ipilimumab versus lenvatinib or sorafenib for US and Chinese patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
- PERI-START: a phase II trial of perioperative TACE, tislelizumab, and lenvatinib in early-stage hepatocellular carcinoma.
- Multisite long-read sequencing reveals the early contributions of somatic structural variations to HBV-related hepatocellular carcinoma tumorigenesis.
- Enhanced SLC35B2/SAV1 sulfation axis promotes tumor growth by inhibiting Hippo signaling in HCC.
- Identification of Core gene expression alterations regulated by gut microbiota in tumor progression and immunotherapy resistance through integrative pan-cancer analysis.
- The PI3K/Akt/mTOR Pathway: Immuno-Metabolic Orchestration in IR/MASH-Associated Hepatocellular Carcinoma.
- Fractal analysis based on Gd-EOB-DTPA-enhanced MRI for prediction of vessels that encapsulate tumor clusters in patients with hepatocellular carcinoma.
- Liver resection versus radiofrequency ablation for solitary small hepatocellular carcinoma measuring ≤3 cm: a systematic review and meta-analysis.
- Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma.
- Integrative analysis of senescence-related genes identifies robust prognostic clusters with distinct features in hepatocellular carcinoma.
- DDX42 Enhances Hepatocellular Carcinoma Cell Proliferation, Radiation and Sorafenib Resistance via Regulating GRB2 RNA Maturation and Activating PI3K/AKT Pathway.
- Impairing Islets in Newborn Mice Promotes Liver Fibrosis and Carcinoma Development in a Rapid NASH Model.
- CD44 and mitochondria dual-targeted polydopamine nanoplatform for combined chemotherapy, photothermal ablation, and immunogenic cell death induction in liver cancer.
- Wild-Type and rtA181T/sW172* Mutant Strains of Hepatitis B Virus Drive Hepatocarcinogenesis via Distinct GRP78-Mediated ER Stress Pathways.
- A Soluble Triantennary N-Acetylgalactosamine Camptothecin Prodrug for Hepatocellular Carcinoma-Targeted Therapy.
- MMAE-Based Peptide-Drug Conjugates Targeting GPC3 for Precision Chemoradiotherapy in Hepatocellular Carcinoma.
- Structure-Guided Optimization and Preclinical Evaluation of 6-O-Benzylguanine-Based Pin1 Inhibitor for Hepatocellular Carcinoma Treatment.
- Synergistic Ultrasound-Activable Artificial Enzyme and Precision Gene Therapy to Suppress Redox Homeostasis and Malignant Phenotypes for Controllably Combating Hepatocellular Carcinoma.
- A prognostic score based on early recurrence-related factors for hepatocellular carcinoma patients with microvascular invasion after hepatectomy.
- Tumor burden score combined with AFP and PIVKA-II (TAP score) to predict the prognosis of hepatocellular carcinoma patients after radical liver resection.
- MRI-Based Topology Deep Learning Model for Noninvasive Prediction of Microvascular Invasion and Assisting Prognostic Stratification in HCC.
- Unveiling causal links between serum amino acid levels and risk of hepatobiliary neoplasms by Mendelian randomization study.
- Pathogenesis and Systemic Treatment of Hepatocellular Carcinoma: Current Status and Prospects.
- FBP1 controls liver cancer evolution from senescent MASH hepatocytes.
- The protein circPETH-147aa regulates metabolic reprogramming in hepatocellular carcinoma cells to remodel immunosuppressive microenvironment.
- Loss of NUMB promotes hepatomegaly and hepatocellular carcinoma through the AKT/glycogen/hippo signaling.
- RBM39 promotes hepatocarcinogenesis by regulating RFX1's alternative splicing and subsequent activation of integrin signaling pathway.
- CAR-T cell engineered with TCR-like antibody specific for HBV surface antigen epitope E183-91/HLA-A *0201 exhibit potent activity against HBV-HCC.
- Immunogenic Cell Death Genes Related Prognostic Biomarker in Hepatocellular Carcinoma.
- Hypoxia-induced exosomal lncRNA-PVT1 as a biomarker and mediator of EMT in hepatocellular carcinoma.
- EMP2 promotes hepatocellular carcinoma proliferation and invasion by activating cellular autophagy.
- Progressed Atrioventricular Block in Immune Checkpoint Inhibitor Induced Myocarditis: A Case Report.
- Identification and functional analysis of five hub lncRNAs associated with oncogenesis of Hepatocellular Carcinoma.
- Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of hepatocellular carcinoma: A systematic review and meta-analysis.
- Histone lactylation drives liver cancer metastasis by facilitating NSF1-mediated ferroptosis resistance after microwave ablation.
- Comprehensive multi-phase 3D contrast-enhanced CT imaging for primary liver cancer.
- Integrating bulk and single cell sequencing data to identify prognostic biomarkers and drug candidates in HBV associated hepatocellular carcinoma.
- Preparation of iodine-131 labeled Polyvinyl alcohol-collagen microspheres for radioembolization therapy of liver tumors.
- TERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosis.
- KAT2A-driven succinylation of SRSF11 enforces spliceosome-mediated RAD52 splicing to promote homologous recombination and radioresistance in hepatocellular carcinoma.
- Ultrasensitive Electrochemical Screening of Circulating Tumor Cells Over Single-Atom Nanozyme Integrated 3D Nanoarray.
- Indocyanine green fluorescence staining-guided laparoscopic posterosuperior segmentectomy: A multicenter retrospective cohort study.
- Indocyanine green fluorescence imaging (ICG-FI) in difficult laparoscopic hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matched analysis.
- Comparison of textbook outcomes between laparoscopic and open liver resection for patients with hepatocellular carcinoma: a multicenter study.
- Effect of 15- or 25-min intermittent Pringle maneuver on early recurrence of hepatocellular carcinoma after hepatectomy: a protocol for a randomized controlled trial.
- Short- and long-term outcomes following laparoscopic liver resection for hepatocellular carcinoma combined with type I/II portal vein tumor thrombus.
- Three-dimensional location approach with silk thread guided hepatectomy for liver tumor.
- Current status of drug therapy for chronic hepatitis B.
- Intraoperative Blood Transfusion has a Distinct Impact on the Long-Term Prognosis of Hepatocellular Carcinoma Patients With Different Alpha-Fetoprotein-Tumor Burden Scores After Liver Resection: A Large-Scale Multicenter Study.
- Therapeutic efficacy of hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a propensity score matching study.
- Predictive value of combined Albumin-Globulin score and psoas muscle index for postoperative prognosis in combined hepatocellular carcinoma and cholangiocarcinoma.
- Short- and medium-term impacts of unplanned intraoperative conversion during laparoscopic liver resection for hepatocellular carcinoma patients: a propensity score-matched study.
- Gold Nano Frameworks with Mesopores for Synergistic Immune-Thermal Therapy in Hepatic Carcinoma: A Paradigm Shift in Immune Checkpoint Blockade.
- Quantitative diffusion weighted imaging in patients with hepatocellular carcinoma: effects of simultaneous multi-slice acceleration and gadoxetic acid administration.
- Diagnostic performance of magnetic resonance imaging and contrast-enhanced ultrasound in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma: a meta-analysis.
- Noninvasive identification of SOX9 status using radiomics signatures may help construct personalized treatment strategy in hepatocellular carcinoma.
- The Impact of Imaging-Diagnosed Sarcopenia on Long-term Prognosis After Curative Resection for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
- Oxidative Stress Promotes Liver Cancer Metastasis via RNF25-Mediated E-Cadherin Protein Degradation.
- Dual Enzyme-Locked Activation Reporter for Accurate Liver Cancer Surveillance.
- Steric Hindrance-Mediated Enzymatic Reaction Enable Homogeneous Dual Fluorescence Indicators Aptasensing of Hepatocellular Carcinoma CTCs.
- Pure Laparoscopic Anatomic Resection of Liver Segment 4 with Middle Hepatic Vein Involvement Using Indocyanine Green Fluorescence Staining.
- Laparoscopic Anatomical Cranial Sub-segmentectomy of Segment VII (S7) with Super-Selective Intra-arterial Nano-ICG Positive Staining-Guided Trans-Parenchymal Approach.
- Laparoscopic Anatomic Bi-segmentectomy (S5 and S6) Using Takasaki's Approach and Indocyanine Green Fluorescence Navigation.
- Novel CAR-T cells targeting TRKB for the treatment of solid cancer.
- Transhepatic arterial approaches for ICG injection to guide laparoscopic anatomical hepatectomy: A case series study.
- Enhanced prognosis of HCC patients undergoing radical treatments with tenofovir versus entecavir: A meta-analysis based on propensity score matching studies.
- Effect of tenofovir versus entecavir on the long-term prognosis in hepatocellular carcinoma patients with concurrent metabolic dysfunction-associated steatotic liver disease and hepatitis B.
- Role of microvascular invasion in early recurrence of hepatocellular carcinoma after liver resection: A literature review.
- Clinicopathological characteristics and prognosis of combined hepatocellular cholangiocarcinoma.
- Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
- Does depressurization of the portal vein before liver transplantation affect the recurrence of HCC? A nested case-control study.
- Impact of hepatic inflammation and fibrosis on the recurrence and long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after hepatectomy.
- Identification of CD8+ T-cell exhaustion signatures for prognosis in HBV-related hepatocellular carcinoma patients by integrated analysis of single-cell and bulk RNA-sequencing.
- Evaluating the diagnostic accuracy of heat shock proteins and their combination with Alpha-Fetoprotein in the detection of hepatocellular carcinoma: a meta-analysis.
- The effectiveness of problem-based learning and case-based learning teaching methods in clinical practical teaching in TACE treatment for hepatocellular carcinoma in China: a bayesian network meta-analysis.
- Prognostic significance of cyclin-dependent kinase subunit 2 (CKS2) in malignant tumours: a meta-analysis and bioinformatic analysis.
- Inhibiting Pink1/Parkin-mediated mitophagy enhances the anticancer effects of quercetin in hepatocellular carcinomaf.
- DDX39B protects against sorafenib-induced ferroptosis by facilitating the splicing and cytoplasmic export of GPX4 pre-mRNA in hepatocellular carcinoma.
- UBAP2 contributes to radioresistance by enhancing homologous recombination through SLC27A5 ubiquitination in hepatocellular carcinoma.
- A facile boronophenylalanine modified polydopamine dual drug-loaded nanoparticles for enhanced anti-tumor immune response in hepatocellular carcinoma comprehensive treatment.
- The role of cholesterol-modified prognostic nutritional index in nutritional status assessment and predicting survival after liver resection for hepatocellular carcinoma.
- PIVKA-II combined with tumor burden score to predict long-term outcomes of AFP-negative hepatocellular carcinoma patients after liver resection.
- Effect of nucleos(t)ide analogue discontinuation on the prognosis of HBeAg-negative hepatitis B virus-related hepatocellular carcinoma after hepatectomy: A propensity score matching analysis.
- Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
- NR0B1 augments sorafenib resistance in hepatocellular carcinoma through promoting autophagy and inhibiting apoptosis.
- SUMOylation of annexin A6 retards cell migration and tumor growth by suppressing RHOU/AKT1-involved EMT in hepatocellular carcinoma.
- Repaglinide restrains HCC development and progression by targeting FOXO3/lumican/p53 axis.
- Hyperpolarized 13 C MRI in hepatocellular carcinoma: Unmet questions during clinical translation.
- Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis.
- A refined therapeutic plan based on the machine-learning prognostic model of liver hepatocellular carcinoma.
- Targeting oncogenic transcriptional factor c-myc by oligonucleotide PROTAC for the treatment of hepatocellular carcinoma.
- Extracellular contrast agent-enhanced MRI is as effective as gadoxetate disodium-enhanced MRI for predicting microvascular invasion in HCC.
- Meta-analysis of prognostic factors for overall survival and disease-free survival among resected patients with combined hepatocellular carcinoma and cholangiocarcinoma.
- Tumor burden score is superior to primary liver cancer stages in predicting prognosis for patients with combined hepatocellular-cholangiocarcinoma after surgery: A multi-center study.
- Prognostic MRI features to predict postresection survivals for very early to intermediate stage hepatocellular carcinoma.
- Apparent diffusion coefficient and tissue stiffness are associated with different tumor microenvironment features of hepatocellular carcinoma.
- miRNAs in patients with alcoholic liver disease: a systematic review and meta-analysis.
- Targeted degradation of NDUFS1 by agrimol B promotes mitochondrial ROS accumulation and cytotoxic autophagy arrest in hepatocellular carcinoma.
- Targeting cell death mechanisms: the potential of autophagy and ferroptosis in hepatocellular carcinoma therapy.
- Extrachromosomal circular MiR-17-92 amplicon promotes HCC.
- Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC.
- Letter to the Editor: Is the evidence convincing for the expansion of CHB treatment criteria to reduce the risk of HCC?
- BMP9-ID1 Pathway Attenuates N6-Methyladenosine Levels of CyclinD1 to Promote Cell Proliferation in Hepatocellular Carcinoma.
- NIR-II-Absorbing NDI Polymer with Superior Penetration Depth for Enhanced Photothermal Therapy Efficiency of Hepatocellular Carcinoma.
- Multimodal imaging-based prediction of recurrence for unresectable HCC after downstage and resection-cohort study.
- A commentary on 'Global research status and frontiers on autophagy in hepatocellular carcinoma: a comprehensive bibliometric and visualized analysis'.
- A commentary on 'Survival benefit of liver resection following complete response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a retrospective, multicenter, cohort study'.
- A commentary on 'Effect of transarterial chemoembolization as postoperative adjuvant therapy for intermediate stage hepatocellular carcinoma with microvascular invasion: a multicenter cohort study'.
- Inhibition of NPC1 suppresses cell proliferation and β-catenin signaling activation of liver cancer.
- A flexible deep learning framework for liver tumor diagnosis using variable multi-phase contrast-enhanced CT scans.
- Roles of peroxisome proliferator-activated receptors in hepatocellular carcinoma.
- Integrated Single-Cell and Spatial Transcriptome Reveal Metabolic Gene SLC16A3 as a Key Regulator of Immune Suppression in Hepatocellular Carcinoma.
- Oxidative stress induces extracellular vesicle release by upregulation of HEXB to facilitate tumour growth in experimental hepatocellular carcinoma.
- RNA-binding protein Trx regulates alternative splicing and promotes metastasis of HCC via interacting with LINC00152.
- Exosomal mRNA in plasma serves as a predictive marker for microvascular invasion in hepatocellular carcinoma.
- Hepatic Steatosis Has No Effect in Diagnosis Accuracy of LI-RADS v2018 Categorization of Hepatocellular Carcinoma in MR Imaging.
- Discovery of 5-(Piperidin-4-yl)-1,2,4-oxadiazole Derivatives as a New Class of Human Caseinolytic Protease P Agonists for the Treatment of Hepatocellular Carcinoma.
- Treatments for Early Hepatocellular Carcinoma: Resection or Ablation-How to Make a Decision.
- Deep learning-based compressed SENSE improved diffusion-weighted image quality and liver cancer detection: A prospective study.
- Diagnostics and omics technologies for the detection and prediction of metabolic dysfunction-associated steatotic liver disease-related malignancies.
- Combining a glycolysis‑related prognostic model based on scRNA‑Seq with experimental verification identifies ZFP41 as a potential prognostic biomarker for HCC.
- Focal liver lesion diagnosis with deep learning and multistage CT imaging.
- FBXO7 ubiquitinates PRMT1 to suppress serine synthesis and tumor growth in hepatocellular carcinoma.
- METTL3-mediated m6A modification of lncRNA TSPAN12 promotes metastasis of hepatocellular carcinoma through SENP1-depentent deSUMOylation of EIF3I.
- Glycogen metabolism-mediated intercellular communication in the tumor microenvironment influences liver cancer prognosis.
- Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment.
- Comprehensive analysis of bioinformatics and system biology reveals the association between Girdin and hepatocellular carcinoma.
- Prognostic Implications of MRI-assessed Intratumoral Fat in Hepatocellular Carcinoma: An Asian and European Cohort Study.
- LI-RADS CT and MRI Ancillary Feature Association with Hepatocellular Carcinoma and Malignancy: An Individual Participant Data Meta-Analysis.
- Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
- Hypoxia-induced nuclear localization of ubiquinol-cytochrome-c reductase complex assembly factor 3 (UQCC3) in hepatocellular carcinoma.
- Use of indocyanine green-human serum albumin complexes in fluorescence image-guided laparoscopic anatomical liver resection: a case series study (with video).
- Impact of metabolic dysfunction-associated fatty liver disease on the outcomes following laparoscopic hepatectomy for hepatocellular carcinoma.
- Caudo-dorsal approach combined with the occlusion of right hepatic vein and Pringle maneuver in laparoscopic anatomical resection of segment 7.
- Liver transplantation for advanced hepatocellular carcinoma after downstaging with consequential lenvatinib, transcatheter arterial chemoembolization and camrelizumab.
- Neoadjuvant therapy of sequential TACE, camrelizumab, and apatinib for single huge hepatocellular carcinoma (NEO-START): study protocol for a randomized controlled trial.
- Prognostic value of preoperative systemic immune-inflammation index/albumin for patients with hepatocellular carcinoma undergoing curative resection.
- Radiofrequency ablation versus laparoscopic hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis.
- Laparoscopic Anatomical Resection of Paracaval Portion of Caudate Lobe and Segment 8 for HCC in an HCV-Related Cirrhotic Patient.
- Remarkable response of PD-1 antibody plus lenvatinib as the second-line treatment for combined hepatocellular-cholangiocarcinoma: Report of two cases.
- Gamma-glutamyl transpeptidase to albumin ratio holds a prognostic significance after hepatectomy in patients with hepatocellular carcinoma and liver cirrhosis.
- Efficacy of LR-5 and LR-4/5 by Liver Imaging Reporting and Data System (MRI) for hepatocellular carcinoma: A meta-analysis.
- Rupture and hemorrhage of a large primary liver tumor in caudate lobe.
- Hepatocyte-specific HDAC3 ablation promotes hepatocellular carcinoma in females by suppressing Foxa1/2.
- Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: a systematic review and meta-analysis.
- A new method for predicting the microvascular invasion status of hepatocellular carcinoma through neural network analysis.
- The prognostic nutritional index and tumor pathological characteristics predict the prognosis of elderly patients with early-stage hepatocellular carcinoma after surgery.
- FOXA2 plays a critical role in hepatocellular carcinoma progression and lenvatinib-associated drug resistance.
- Incidence and trends of hepatic cancer among children and adolescents in the United States from 2000 to 2017: Evidence from the Surveillance, Epidemiology, and End Results registry data.
- Effect of PIVKA-II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery.
- Insurance status impacts survival of hepatocellular carcinoma patients after liver resection.
- Risk factors of postoperative bile leakage after liver resection: A systematic review and meta-analysis.
- Repeat hepatic resection combined with intraoperative radiofrequency ablation versus repeat hepatic resection alone for recurrent and multiple hepatocellular carcinoma patients meeting the Barcelona Clinic Liver Cancer stage A: A propensity
- Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis.
- HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation.
- DDX39B facilitates the malignant progression of hepatocellular carcinoma via activation of SREBP1-mediated de novo lipid synthesis.
- Glutamine synthetase-negative hepatocellular carcinoma has better prognosis and response to sorafenib treatment after hepatectomy.
- Effects of viral load on tenofovir vs. entecavir efficacy in recurrence prevention of hepatitis B virus-related hepatocellular carcinoma.
- Primary Hepatocellular Carcinoma Revealed on 68 Ga-DOTATATE in a Patient With Nasopharyngeal Carcinoma.
- The value of MRI in predicting hepatocellular carcinoma with cytokeratin 19 expression: a systematic review and meta-analysis.
- Deciphering the immune heterogeneity dominated by natural killer cells with prognostic and therapeutic implications in hepatocellular carcinoma.
- EMT-Related Gene Signature: A New Method for Personalized Risk Assessment in Patients with Hepatocellular Carcinoma.
- TEA Domain Transcription Factor 1 Inhibits Ferroptosis and Sorafenib Sensitivity of Hepatocellular Carcinoma Cells.
- Dysregulated cholesterol regulatory genes in hepatocellular carcinoma.
- Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of FGFR4 in wild-type and gatekeeper mutants.
- Preclinical evaluation of 68Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma.
- Preoperative MRI-based multiparametric model for survival prediction in hepatocellular carcinoma patients with portal vein tumor thrombus following hepatectomy.
- Nomogram to predict liver surgery-specific complications for hepatocellular carcinoma: A multicenter study.
- Development and validation of the OSASH score to predict overall survival of hepatocellular carcinoma after surgical resection: a dual-institutional study.
- Intravoxel incoherent motion diffusion weighted imaging for preoperative evaluation of liver regeneration after hepatectomy in hepatocellular carcinoma.
- Quality of radiomics for predicting microvascular invasion in hepatocellular carcinoma: a systematic review.
- Ferroptosis signaling promotes the release of misfolded proteins via exosomes to rescue ER stress in hepatocellular carcinoma.
- HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma.
- Hepatitis B virus infection: An insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk.
- Lnc-AIFM2-1 promotes HBV immune escape by acting as a ceRNA for miR-330-3p to regulate CD244 expression.
- The appropriate method of hepatectomy for hepatocellular carcinoma within University of California San Francisco (UCSF) criteria through neural network analysis.
- Clinical prognosis and related molecular features of hepatitis B-associated adolescent and young adult hepatocellular carcinoma.
- HGF-Based CAR-T Cells Target Hepatocellular Carcinoma Cells That Express High Levels of c-Met.
- Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD).
- Construction of Two Independent RAB Family-Based Scoring Systems Based on Machine Learning Algorithms and Definition of RAB13 as a Novel Therapeutic Target for Hepatocellular Carcinoma.
- USP35 promotes hepatocellular carcinoma progression by protecting PKM2 from ubiquitination‑mediated degradation.
- Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle's maneuver for hepatocellular carcinoma: a randomized controlled trial.
- Liver cancer stem cell dissemination and metastasis: uncovering the role of NRCAM in hepatocellular carcinoma.
- Parenchymal Sparing Laparoscopic Segmentectomy III and IV with Indocyanine Green Fluorescence Negative Stain Method Using Glisson Pedicle Approach.
- Meta-analysis of Prognostic Factors for Overall Survival Among Resected Patients with Spontaneous Ruptured Hepatocellular Carcinoma.
- The current role of radiofrequency ablation in the treatment of intrahepatic recurrent hepatocellular carcinoma.
- Increased Small Ubiquitin-like Modifier-Activating Enzyme SAE1 Promotes Hepatocellular Carcinoma by Enhancing mTOR SUMOylation.
- Tumor burden score-AFP-albumin-bilirubin grade score predicts the survival of patients with hepatocellular carcinoma after liver resection.
- Discovery of canine drug toceranib phosphate as a repurposed agent against human hepatocellular carcinoma.
- circPSD3 is a promising inhibitor of uPA system to inhibit vascular invasion and metastasis in hepatocellular carcinoma.
- PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma.
- Prognostic factors of nivolumab in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
- Hollow MnO2-Based Nanoprobes for Enhanced Photothermal/Photodynamic /Chemodynamic Co-Therapy of Hepatocellular Carcinoma.
- Upper-critical solution temperature (UCST) polymer functionalized nanomedicine for controlled drug release and hypoxia alleviation in hepatocellular carcinoma therapy.
- Universal Liver Imaging Lexicon: Imaging Atlas for Research and Clinical Practice.
- Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis.
- Development of a Model including MRI Features for Predicting Advanced-stage Recurrence of Hepatocellular Carcinoma after Liver Resection.
- Hepatocellular Carcinoma: It Is Time to Focus on Prognosis.
- Imaging to Predict Prognosis in Hepatocellular Carcinoma: Current and Future Perspectives.
- VICT2 Trait: Prognostic Alternative to Peritumoral Hepatobiliary Phase Hypointensity in HCC.
- Prognostic nomograms for HBV-related BCLC 0-a stage hepatocellular carcinoma incorporating aspartate aminotransferase to albumin ratio.
- Targeting PSAT1 to mitigate metastasis in tumors with p53-72Pro variant.
- Programmed cell death protein 1 and tyrosine kinase inhibition plus transcatheter arterial chemoembolization of advanced hepatocellular carcinoma.
- Hierarchically tumor-activated nanoCRISPR-Cas13a facilitates efficient microRNA disruption for multi-pathway-mediated tumor suppression.
- The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial.
- Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle's maneuver for hepatocellular carcinoma: protocol for a randomized controlled trial.
- Laparoscopic versus open liver resection for intrahepatic cholangiocarcinoma: a systematic review of propensity score-matched studies.
- Treatments for recurrent hepatocellular carcinoma: laparoscopic or open repeat liver resection, how to make a decision?
- Hepatitis B Virus X Protein Modulates p90 Ribosomal S6 Kinase 2 by ERK to Promote Growth of Hepatoma Cells.
- Simultaneous Homogeneous Fluorescence Detection of AFP and GPC3 in Hepatocellular Carcinoma Clinical Samples Assisted by Enzyme-Free Catalytic Hairpin Assembly.
- 131I-Labeled Silk Fibroin Microspheres for Radioembolic Therapy of Rat Hepatocellular Carcinoma.
- Association of the Modified Albumin-Bilirubin Grade with Survival Outcomes in Esophageal Squamous Cell Carcinoma.
- Hepatic Resection Combined with Intraoperative Radiofrequency Ablation Versus Hepatic Resection Alone for Selected Patients with Moderately Advanced Multifocal Hepatocellular Carcinomas.
- ASO Author Reflections: How to Choose the Optimal Strategy to Treat Patients with Moderately Advanced Multifocal Hepatocellular Carcinomas?
- ASO Author Reflections: Pure Laparoscopic Right Upper Transversal Hepatectomy.
- Pure Laparoscopic Right Upper Transversal Hepatectomy.
- ASO Author Reflections: How to Choose the Optimal Surgical Strategy to Finish Laparoscopic Anatomical Hepatectomy for a Solitary HCC in the Left Lobe?
- Laparoscopic Segmentectomy IV Using Hepatic Round Ligament Approach Combined with Fluorescent Negative Staining Method.
- Primary hepatic gastrointestinal stromal tumor: A case series.
- Effects of preoperative oral carbohydrate administration combined with postoperative early oral intake in elderly patients undergoing hepatectomy with acute-phase inflammation and subjective symptom burden: A prospective randomized controll
- Novel postoperative nomograms for predicting individual prognoses of hepatitis B-related hepatocellular carcinoma with cirrhosis.
- Preoperative aspartate aminotransferase to albumin ratio correlates with tumor characteristics and predicts outcome of hepatocellular carcinoma patients after curative hepatectomy: a multicenter study.
- Preoperative and postoperative nomograms for predicting early recurrence of hepatocellular carcinoma without macrovascular invasion after curative resection.
- The impact of tumor burden at the initial hepatectomy on the recurrence-to-death survival after repeat surgical resection/radiofrequency ablation: a retrospective study.
- Tumour site is a risk factor for hepatocellular carcinoma after hepatectomy: a 1:2 propensity score matching analysis.
- Liver transplantation in China: Achievements over the past 30 years and prospects for the future.
- The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update.
- Use of chemotherapy to treat hepatocellular carcinoma.
- A detailed multi-omics analysis of GNB2 gene in human cancers.
- The lipid transporter HDLBP promotes hepatocellular carcinoma metastasis through BRAF-dependent epithelial-mesenchymal transition.
- Sarcopenia predicts an adverse prognosis in patients with combined hepatocellular carcinoma and cholangiocarcinoma after surgery.
- Prognostic value of exosomal noncoding RNA in hepatocellular carcinoma: a meta-analysis.
- New classification-oriented laparoscopic anatomical hepatectomy strategy for hepatocellular carcinoma invading two or more (sub)segments in the left lobe.
- Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis.
- Conversion resection for patients with hepatocellular carcinoma and inferior vena cava tumor thrombus: a consecutive case series.
- Safety of elective hepatectomy performed on weekend for patients with hepatocellular carcinoma.
- Upregulation of SERPINE2 Results in Poor Prognosis of Hepatoblastoma via Promoting Invasion Abilities.
- Disrupting metformin adaptation of liver cancer cells by targeting the TOMM34/ATP5B axis.
- Aspirin for the prevention of hepatocellular carcinoma: an updated meta-analysis with particular focus on patients with chronic liver disease.
- Profiling hepatocellular carcinoma aggressiveness with contrast-enhanced ultrasound and gadoxetate disodium-enhanced MRI: An intra-individual comparative study based on the Liver Imaging Reporting and Data System.
- Deep learning radiomics based on contrast enhanced computed tomography predicts microvascular invasion and survival outcome in early stage hepatocellular carcinoma.
- Clinicopathologic features, treatment, survival, and prognostic factors of combined hepatocellular and cholangiocarcinoma: A nomogram development based on SEER database and validation in multicenter study.
- The effect of trans arterial chemoembolization in the management of intrahepatic cholangiocarcinoma. A systematic review and meta-analysis.
- Comparison of a preoperative MR-based recurrence risk score versus the postoperative score and four clinical staging systems in hepatocellular carcinoma: a retrospective cohort study.
- A novel medication decision gene signature predicts response to individualized therapy and prognosis outcomes in hepatocellular carcinoma patients.
- Preoperative prediction of glypican-3 positive expression in solitary hepatocellular carcinoma on gadoxetate-disodium enhanced magnetic resonance imaging.
- Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis.
- A Novel Artificial Neural Network Prognostic Model Based on a Cancer-Associated Fibroblast Activation Score System in Hepatocellular Carcinoma.
- Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm.
- Fas -670 A/G polymorphism predicts prognosis of hepatocellular carcinoma after curative resection in Chinese Han population.
- Overexpression of transcription factor 3 drives hepatocarcinoma development by enhancing cell proliferation via activating Wnt signaling pathway.
- Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
- Association of the MARCO polymorphism rs6761637 with hepatocellular carcinoma susceptibility and clinical characteristics.
- Construction and validation of an IRF4 risk score to predict prognosis and response to immunotherapy in hepatocellular carcinoma.
- The role and mechanism of noncoding RNAs in regulation of metabolic reprogramming in hepatocellular carcinoma.
- BMP9-ID1 Signaling Activates HIF-1α and VEGFA Expression to Promote Tumor Angiogenesis in Hepatocellular Carcinoma.
- Hemihepatic versus total hepatic inflow occlusion for laparoscopic hepatectomy: A randomized controlled trial.
- Benefit of a Live Donor for Patients With Hepatocellular Carcinoma on the Waiting List.
- Sarcomatoid hepatocellular carcinoma versus conventional hepatocellular carcinoma: a systematic review and meta-analysis.
- OGG1 contributes to hepatocellular carcinoma by promoting cell cycle-related protein expression and enhancing DNA oxidative damage repair in tumor cells.
- A cascaded copper-based nanocatalyst by modulating glutathione and cyclooxygenase-2 for hepatocellular carcinoma therapy.
- LncRNA CEBPA-DT promotes liver cancer metastasis through DDR2/β-catenin activation via interacting with hnRNPC.
- TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
- A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Considerations.
- Comprehensive Landscape of ARID Family Members and Their Association with Prognosis and Tumor Microenvironment in Hepatocellular Carcinoma.
- Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity.
- Modifying LI-RADS on Gadoxetate Disodium-Enhanced MRI: A Secondary Analysis of a Prospective Observational Study.
- The Value of Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis.
- Prognostic implications of CT/MRI LI-RADS in hepatocellular carcinoma: State of the art and future directions.
- Predicting microvascular invasion in hepatocellular carcinoma: A dual-institution study on gadoxetate disodium-enhanced MRI.
- Long noncoding RNA TLNC1 promotes the growth and metastasis of liver cancer via inhibition of p53 signaling.
- UBE2O promotes lipid metabolic reprogramming and liver cancer progression by mediating HADHA ubiquitination.
- Transarterial chemoembolization vs. liver resection as initial treatment for hepatocellular carcinoma occurring exclusively in caudate lobe: A retrospective propensity matching analysis.
- A Macrophage Differentiation-Mediated Gene: DDX20 as a Molecular Biomarker Encompassing the Tumor Microenvironment, Disease Staging, and Prognoses in Hepatocellular Carcinoma.
- Uvangoletin, extracted from Sarcandra glabra, exerts anticancer activity by inducing autophagy and apoptosis and inhibiting invasion and migration on hepatocellular carcinoma cells.
- HDLBP-stabilized lncFAL inhibits ferroptosis vulnerability by diminishing Trim69-dependent FSP1 degradation in hepatocellular carcinoma.
- A randomized controlled trial of effect of 15- or 25-minute intermittent Pringle maneuver on hepatectomy for hepatocellular carcinoma.
- Patterns, timing, and predictors of recurrence after laparoscopic liver resection for hepatocellular carcinoma: results from a high-volume HPB center.
- Laparoscopic anatomic bi-segmentectomy (S3 and S4b) using the Glisson's pedicle-first and intrahepatic anatomic markers approach.
- Trocar layouts in laparoscopic liver surgery.
- Is the anterior approach suitable for laparoscopic right hemihepatectomy in patients with large HCC (5-10 cm)? A propensity score analysis.
- Radioactive Iodine Therapy Does not Improve Cancer-specific Survival in Hürthle Cell Carcinoma of the Thyroid.
- Laparoscopic versus open liver resection for resectable HCC with BCLC stage B: a propensity score-matched analysis.
- Four-year experience with more than 1000 cases of total laparoscopic liver resection in a single center.
- Differentiating malignant and benign focal liver lesions in children using CEUS LI-RADS combined with serum alpha-fetoprotein.
- Radiomics signature: A potential biomarker for β-arrestin1 phosphorylation prediction in hepatocellular carcinoma.
- Integrative analysis identifies key mRNA biomarkers for diagnosis, prognosis, and therapeutic targets of HCV-associated hepatocellular carcinoma.
- Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations.
- The density of tumor-infiltrating lymphocytes and prognosis in resectable hepatocellular carcinoma: a two-phase study.
- Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: a case report.
- Prediction of Prognosis for cHCC-CC Patients After Surgery: Comparison of Tumor Marker Score Based on AFP, CEA, CA19-9, and Other Clinical Stages.
- The selective serotonin reuptake inhibitors enhance the cytotoxicity of sorafenib in hepatocellular carcinoma cells.
- The prognostic value of aspartate aminotransferase-to-lymphocyte ratio index in early-stage hepatocellular carcinoma after hepatectomy: A propensity-score matched analysis.
- 18-FDG PET/CT provides solid evidence of microvascular invasion and is correlated with prognosis in patients with hepatocellular carcinoma.
- Thrombocytopenia predicts the prognosis of hepatocellular carcinoma patients with Ishak score 6 after hepatectomy: A propensity score matching analysis.
- Comparison of preoperative two-dimensional shear wave elastography, indocyanine green clearance test and biomarkers for post hepatectomy liver failure prediction in patients with hepatocellular carcinoma.
- Postoperative controlling nutritional status score is an independent risk factor of survival for patients with small hepatocellular carcinoma: a retrospective study.
- Long non-coding RNA LOC107985656 represses the proliferation of hepatocellular carcinoma cells through activation of the tumor-suppressive Hippo pathway.
- The multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus.
- Combination of albumin-bilirubin grade and clinically significant portal hypertension predicts the prognosis of patients with hepatocellular carcinoma after liver resection.
- Targeting Na+ /K+ -ATPase by berbamine and ouabain synergizes with sorafenib to inhibit hepatocellular carcinoma.
- Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: A multicenter study.
- Sustained and targeted delivery of siRNA/DP7-C nanoparticles from injectable thermosensitive hydrogel for hepatocellular carcinoma therapy.
- Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma.
- Distinct functions of transforming growth factor-β signaling in c-MYC driven hepatocellular carcinoma initiation and progression.
- Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis.
- YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin.
- Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy.
- MiR-378a-3p as a putative biomarker for hepatocellular carcinoma diagnosis and prognosis: Computational screening with experimental validation.
- The importance of a nonsmooth tumor margin and incomplete tumor capsule in predicting HCC microvascular invasion on preoperative imaging examination: a systematic review and meta-analysis.
- HBV upregulated triggering receptor expressed on myeloid cells-1 (TREM-1) expression on monocytes participated in disease progression through NF-Kb pathway.
- Prediction of Remnant Liver Regeneration after Right Hepatectomy in Patients with Hepatocellular Carcinoma Using Preoperative CT Texture Analysis and Clinical Features.
- Laparoscopic liver resection for hepatocellular carcinoma presents less respiratory complications compared with open procedure: A propensity score analysis in the elderly.
- Macrotrabecular-massive hepatocellular carcinoma: imaging identification and prediction based on gadoxetic acid-enhanced magnetic resonance imaging.
- Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
- Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features.
- LI-RADS category 5 hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MRI for early recurrence risk stratification after curative resection.
- Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics.
- Peritumoral Tertiary Lymphoid Structures Correlate With Protective Immunity and Improved Prognosis in Patients With Hepatocellular Carcinoma.
- Long-term follow-up of HCV patients with sustained virological response after treatment with pegylated interferon plus ribavirin.
- Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
- Letter to the Editor: Statin Reduces the Risk of Hepatocellular Carcinoma Development in Patients With CHB.
- Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma.
- The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
- Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child-Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF)
- Prognostic evaluation and immune infiltration analysis of five bioinformatic selected genes in hepatocellular carcinoma.
- The Different Effects of Nucleotide and Nucleoside Analogues on the Prognosis of HBV-Related HCC After Curative Resection.
- Integrated proteogenomic analysis revealed the metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma.
- Baseline HBV-DNA load plus AST/ALT ratio predicts prognosis of HBV-related hepatocellular carcinoma after hepatectomy: A multicentre study.
- Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states.
- Donafenib treatment for hepatocellular carcinoma: A case report.
- Successful management of the hepatocellular carcinoma with inferior vena cava tumor thrombus: A case report.
- Thymosin alpha-1 therapy improves postoperative survival after curative resection for solitary hepatitis B virus-related hepatocellular carcinoma: A propensity score matching analysis.
- Prognostic significance of postoperative change of PALBI grade for patients with hepatocellular carcinoma after hepatectomy.
- Diabetes mellitus affects long-term survival in hepatitis B virus-related hepatocellular carcinoma patients: A propensity score-matched analysis.
- Combined prognostic nutritional index and albumin-bilirubin grade to predict the postoperative prognosis of HBV-associated hepatocellular carcinoma patients.
- Outcome of TACE treatment in HIV infected patients with hepatocellular carcinoma.
- Intermedin facilitates hepatocellular carcinoma cell survival and invasion via ERK1/2-EGR1/DDIT3 signaling cascade.
- Efficacy and safety of sorafenib plus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.
- Safety, Efficacy, and Pharmacokinetics of Metatinib Tromethamine Tablet in Patients with Advanced Refractory Solid Tumors: A Phase I Clinical Trial.
- Circular RNA circDLC1 inhibits MMP1-mediated liver cancer progression via interaction with HuR.
- Efficacy of lenvatinib plus pembrolizumab in hepatocellular carcinoma with metachronous lung metastasis: a report of two cases.
- Diagnostic Accuracy of Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for Differentiating Between Hepatocellular Carcinoma and Other Hepatic Malignancies in High-Risk Patients: A Meta-Analysis.
- Comprehensive radiomics nomogram for predicting survival of patients with combined hepatocellular carcinoma and cholangiocarcinoma.
- Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis.
- The impact of thrombocytopenia on prognosis of HBV-related small hepatocellular carcinoma: a propensity score matching analysis.
中文论文(未计入)8
- [Surgical management of multinodular hepatocellular carcinoma: controversies,opportunities,and challenges].
- Expression of signal recognition particle 14 in hepatocellular carcinoma and its relationship with disease progression and patient survival.
- [Status Quo and Development of Immunotherapy for Hepatocellular Carcinoma].
- [Evaluation of clinical safety and diagnostic efficacy of domestic liver-specific magnetic resonance contrast agent (gadoxetate disodium)].
- [Prognosis prediction model for hepatocellular carcinoma based on autophagy related genes].
- [Fucoidan-Modified Phase-Transitional Contrast Agent for Ultrasound Imaging and Targeting of Hepatoma Cells].
- [Mechanism of miRNA-3679 Inhibiting Downstream ZADH2-Target Genes to Promote Hepatocellular Carcinoma Cell Proliferation].
- [Impact of treatment compliance in chronic hepatitis B].
它在 ClinicalTrials.gov 上的全部试验(任何状态)65
- Integration of Imaging, Molecular, Pathological, and Clinical Outcome Data in Hepatocellular Carcinoma.
- YMN-A02 for Advanced Primary Hepatocellular Carcinoma.
- Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
- A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
- NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC
- Surgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma
- Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection
- Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection
- PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
- A Study of GV20-0251 in Advanced or Refractory Solid Tumors
- Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma
- Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma
- PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
- Application of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection
- Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT
- Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular Carcinoma
- Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC
- Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC
- Efficacy of Intravenous Lidocaine on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy
- RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection
- Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC
- PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
- The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC
- Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
- Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase 2 Study of WGI-0301 for Advanced HCC
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
- Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
- Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
- Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
- Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma
- A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC
- A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
- Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients
- A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
- A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
- A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
- A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
- A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
- Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC
- The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma
- Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
- A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
- Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma
- A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
- Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
- Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
- Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
- The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects
- A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
- Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma
- A Study to Evaluate SHR-1210 in Subjects With Advanced HCC
- A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
- Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
- Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma
- Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
- Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 168 篇,占 1.7%。
成都有 5 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 15
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
- 分期
- I/II期
- 开始
- 2024-12
- 登记号
- NCT06742411
年龄 18 岁 至 75 岁(登记的条件)
牵头:四川大学华西医院成都
- 即将招募Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma
- 分期
- II期
- 开始
- 2026-02
- 登记号
- NCT07374250
年龄 18 岁 至 75 岁(登记的条件)
牵头:四川大学华西医院成都
- 即将招募Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.
- 分期
- II期
- 开始
- 2026-07
- 登记号
- NCT07655661
年龄 18 岁 至 75 岁(登记的条件)
牵头:四川大学华西医院成都
- 邀请入组Non-surgical Management After NIT for dMMR/MSI-H GC
- 分期
- 未注明
- 开始
- 2026-07
- 登记号
- NCT07646574
年龄 18 岁 至 未注明(登记的条件)
牵头:四川大学华西医院成都
- 正在招募Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- 分期
- III期
- 开始
- 2026-04
- 登记号
- NCT07385703
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛
- 正在招募Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- 分期
- 不分期
- 开始
- 2026-06
- 登记号
- NCT07552402
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南宁、成都、杭州、武汉、石家庄、福州、苏州、银川
- 正在招募Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
- 分期
- II期
- 开始
- 2025-12
- 登记号
- NCT07127822
年龄 18 岁 至 未注明(登记的条件)
牵头:北京大学肿瘤医院;另有 8 家列出的医院为研究中心北京、哈尔滨、天津、太原、成都、石家庄、西安、郑州、青岛
- 正在招募A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- 分期
- II期
- 开始
- 2024-02
- 登记号
- NCT06172478
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心广州、成都
- 正在招募DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
- 分期
- II/III期
- 开始
- 2024-02
- 登记号
- NCT06221748
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、厦门、哈尔滨、徐州、成都、昆明、武汉、济南、郑州、长沙、青岛
- 正在招募A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- 分期
- III期
- 开始
- 2024-11
- 登记号
- NCT06532006
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、石家庄、福州、蚌埠、郑州、重庆、银川、长春、长沙、青岛
- 正在招募A Phase 2 Clinical Study of ABSK061 and ABSK043
- 分期
- II期
- 开始
- 2024-11
- 登记号
- NCT06632262
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、厦门、哈尔滨、天津、太原、徐州、成都、杭州、武汉、沈阳、石家庄、襄阳、贵阳、郑州
- 正在招募A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
- 分期
- I期
- 开始
- 2024-07
- 登记号
- NCT07923214
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、成都、福州
- 正在招募Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
- 分期
- III期
- 开始
- 2023-04
- 登记号
- NCT05918094
年龄 18 岁 至 75 岁(登记的条件)
牵头:中山大学肿瘤防治中心;另有 6 家列出的医院为研究中心上海、南昌、哈尔滨、广州、成都、武汉、郑州
- 正在招募A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
- 分期
- I期
- 开始
- 2022-02
- 登记号
- NCT05262491
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、南昌、天津、成都、杭州、济南
- 即将招募Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD
- 分期
- 未注明
- 开始
- 2025-07
- 登记号
- NCT07088744
年龄 18 岁 至 80 岁(登记的条件)
牵头:海军军医大学第一附属医院(长海医院);另有 1 家列出的医院为研究中心上海、成都
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文168
- The trajectories and predictors of cancer-related fatigue in gastric cancer patients during chemotherapy: A longitudinal study using growth mixture modeling.
- The association between pathological complete response and prognosis of gastric or adenocarcinoma of esophagogastric junction cancer following neoadjuvant chemotherapy: A meta-analysis.
- Intraperitoneal metastasis of gastric cancer: new insights on resident macrophages.
- HER2 regulates autophagy and promotes migration in gastric cancer cells through the cGAS-STING pathway.
- Prognostic value of nutritional risk assessment indices in patients with digestive system tumors.
- Correlation between neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with prognosis in gastric cancer patients undergoing neoadjuvant chemotherapy: a meta-analysis.
- Trends in incidence and mortality of early-onset gastrointestinal cancers: a comprehensive study.
- Burden of gastrointestinal cancers in Asia, 1990-2019.
- Laparoscopic versus open distal gastrectomy with D2 lymphadenectomy following neoadjuvant chemotherapy for locally advanced gastric cancer (CLASS-03b): protocol for a multicentre, randomised, controlled, non-inferiority trial.
- Dihydroartemisinin suppresses metastatic potential and induces apoptosis in gastric adenocarcinoma: An integrative experimental and computational analysis revealing inhibition of MMP14 and promotion of oxidative stress.
- Perioperative chemotherapy for gastric cancer patients with microsatellite instability or deficient mismatch repair: A systematic review and meta-analysis.
- Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors.
- METTL3-driven m⁶A epigenetics in gastric cancer: unveiling oncogenic networks and clinical translation from tumorigenesis to therapy resistance.
- Proportion and Characteristics of Helicobacter Pylori -Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Systematic Review and Meta-Analysis.
- 18 F-FDG PET/CT and 68 Ga-Pentixafor PET/CT Findings of Gastric Mucosa-associated Lymphoid Tissue Lymphoma Transformation to Diffuse Large B-cell Lymphoma.
- Minimally invasive treatment strategies for submucosal tumors of the upper gastrointestinal tract: Advances in innovative endoscopy-based therapies.
- XELOX combined with sintilimab and hyperbaric oxygen therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase Ib/II clinical trial.
- Overall survival according to time-of-day of combined immuno-chemotherapy for advanced gastric cancer: a propensity score-matched analysis.
- Hyperbaric oxygen therapy as an immunosensitizing strategy in advanced gastric hepatoid adenocarcinoma: a case report.
- Integrated analysis of myeloperoxidase in gastric health and cancer: associations with pepsinogen levels, immune regulation, and prognosis in a large healthy population-based and TCGA cohorts.
- Nab-paclitaxel combined with cadonilimab (AK104) as second-line treatment for advanced gastric cancer: protocol for a phase II prospective, multicenter, single-arm clinical trial.
- Identification of core immune-related genes CTSK, C3, and IFITM1 for diagnosing Helicobacter pylori infection-associated gastric cancer through transcriptomic analysis.
- Lidocaine Enhanced Antitumor Efficacy and Relieved Chemotherapy-Induced Hyperalgesia in Mice with Metastatic Gastric Cancer.
- Targeted inhibition of gastric adenocarcinoma by nano-curcumin liposomes: Insights from combined machine learning and experimental analyses into the mechanisms of cuproptosis and metabolic reprogramming.
- Impact of 68Ga-FAPI positron emission tomography/computed tomography on staging and tumor management in patients with gastric cancer.
- GABRD Accelerates Tumour Progression via Regulating CCND1 Signalling Pathway in Gastric Cancer.
- Effects of a Comprehensive Program on Reducing Cancer-Related Fatigue: A Randomized Controlled Trial.
- EZH2 loss promotes gastric squamous cell carcinoma.
- Alkannin triggered apoptosis and ferroptosis in gastric cancer by suppressing lipid metabolism mediated by the c-Fos/SREBF1 axis.
- miRNA-204-5p acts as a tumor suppressor in gastric cancer by inhibiting cell migration, invasion, and glycolysis via the RAB22A/PI3K/AKT axis.
- A novel prognostic model based on migrasome-related LncRNAs for gastric cancer.
- Disparities in overall survival of gastric cancer patients after radical gastrectomy: an age and rural-urban residence-based cohort study with propensity score matching analysis.
- Current status and influencing factors of cancer-related fatigue in gastric cancer patients undergoing chemotherapy: A cross-sectional study.
- The impact of Helicobacter pylori infection on prognosis in patients with postgastrectomy gastric cancer: A systematic review and meta-analysis.
- Correlation of preoperative CT features with intra- and postoperative parameters of endoscopic resection in patients with gastric submucosal tumor (1~3 cm).
- Intraperitoneal chemotherapy for gastric cancer.
- Antimicrobial Resistance Patterns of Clinical Helicobacter pylori Isolates From Gastric Cancer Patients.
- Efficacy and safety of S-1 plus oxaliplatin combined with apatinib and camrelizumab as neoadjuvant therapy for patients with locally advanced gastric or gastroesophageal junction adenocarcinoma: a protocol for a single-arm phase II trial.
- Comparison among Early-Onset, Late-Onset, and Conventional-Onset Adenocarcinoma of Stomach and Esophagogastric Junction: a Retrospective Study.
- A modified liver retraction method decreases liver dysfunction after laparoscopic gastrectomy.
- Enzyme-Responsive Branched Glycopolymer-Based Nanoassembly for Co-Delivery of Paclitaxel and Akt Inhibitor toward Synergistic Therapy of Gastric Cancer.
- Multicriteria optimization achieves superior normal tissue sparing in volumetric modulated arc therapy for gastric cancer.
- Endoscopic morphology of gastric MALT lymphoma correlate with API2/MALT1 fusion and predict treatment response after helicobacter pylori eradication.
- Chemotherapy combined with immunotherapy in patients with gastric cancer: protocol for a systematic review.
- Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastro-oesophageal junction adenocarcinoma: study protocol for a single-arm, phase II clinical trial.
- Neoadjuvant and/or adjuvant chemotherapy for gastric cancer patients with microsatellite instability or deficient mismatch repair: a systematic review and meta-analysis study protocol.
- 68Ga-FAPI-04 positron emission tomography/CT and laparoscopy for the diagnosis of occult peritoneal metastasis in newly diagnosed locally advanced gastric cancer: study protocol of a single-centre prospective cohort study.
- Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy.
- Activation of the FOXM1/ASF1B/PRDX3 axis confers hyperproliferative and antioxidative stress reactivity to gastric cancer.
- Clinicopathological features of hepatoid adenocarcinoma and non-hepatoid adenocarcinoma of the stomach: A systematic review and meta-analysis.
- CAF-secreted LOX promotes PD-L1 expression via histone Lactylation and regulates tumor EMT through TGFβ/IGF1 signaling in gastric Cancer.
- Targeted plasma proteomic analysis uncovers a high-performance biomarker panel for early diagnosis of gastric cancer.
- Maintaining H. pylori Negativity After Eradication Can Consolidate Its Benefit in Gastric Cancer Prevention: A Meta-Analysis.
- Gastric Fundus Splenosis Mimicking Malignancy on FDG PET/CT.
- Malignant gastric outlet obstruction: direct biopsy in the submucosal tunnel to obtain the diagnosis.
- Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer.
- SOX combined with tislelizumab and low-dose radiation therapy for the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase Ib/II clinica
- Effectiveness of PD-1 inhibitor-based first-line therapy in Chinese patients with metastatic gastric cancer: a retrospective real-world study.
- A novel suture technique for a large gastric defect after endoscopic full-thickness resection.
- Comment on "Infectious pathogens and risk of esophageal, gastric and duodenal cancers and ulcers in China: A case-cohort study".
- Combination of dexamethasone and dexmedetomidine as adjuvants of transversus abdominis plane block for postoperative analgesia in gastric cancer patients: A double-blinded randomized controlled trial.
- Gastrointestinal: Chronic anemia caused by diffuse lesions of the stomach.
- Development and Validation of a Computed Tomography-Based Model for Noninvasive Prediction of the T Stage in Gastric Cancer: Multicenter Retrospective Study.
- Structural Optimization and Structure-Activity Relationship of 1H-Pyrazole-4-carboxylic Acid Derivatives as DNA 6mA Demethylase ALKBH1 Inhibitors and Their Antigastric Cancer Activity.
- Involvement of CXC chemokines (CXCL1-CXCL17) in gastric cancer: Prognosis and therapeutic molecules.
- Symptom Cluster Assessment Tools for Gastric Cancer Care in China: A Comprehensive Review.
- The role of microRNAs in the gastric cancer tumor microenvironment.
- Gastric SMARCA4-deficient undifferentiated tumor (SMARCA4-UT): a clinicopathological analysis of four rare cases.
- Traditional Chinese medicine for gastric cancer: An evidence mapping.
- Optimal reconstruction methods after distal gastrectomy for gastric cancer: a protocol for a systematic review and network meta-analysis update.
- Gastric Cancer Signaling Pathways and Therapeutic Applications.
- Uncut Roux-en-Y reconstruction after distal gastrectomy for gastric cancer.
- Managing crawling-type gastric adenocarcinoma with endoscopic techniques and postoperative monitoring.
- Early gastric composite tumor comprising signet-ring cell carcinoma and mucosa-associated lymphoid tissue lymphoma: A case report.
- Exploring non-curative endoscopic submucosal dissection: Current treatment optimization and future indication expansion.
- Distinct oral-associated gastric microbiota and Helicobacter pylori communities for spatial microbial heterogeneity in gastric cancer.
- Effect of statin use on risk and mortality of gastric cancer: a meta-analysis.
- Trends in Incidence, Survival and Mortality of Gastric Cancer in the United States: A Population-Based Study, 2001-2015.
- Study of SOX combined with intraperitoneal high-dose paclitaxel in gastric cancer with synchronous peritoneal metastasis: A phase II single-arm clinical trial.
- CT-determined low skeletal muscle mass predicts worse overall survival of gastric cancer in patients with cachexia.
- Perspectives for immunotherapy of EBV-associated GLELC: A relatively "hot" tumor microenvironment.
- Comparison of long-term quality of life between Billroth-I and Roux-en-Y anastomosis after distal gastrectomy for gastric cancer: a randomized controlled trial.
- Hybrid Endoscopic Submucosal Dissection for Early Gastric Neoplasms: An Ideal Technique?
- Calcified fibrous tumor in the stomach: a rare case of gastric submucosal tumor treated with endoscopic submucosal excavation.
- Gastritis cystica profunda mimicking submucosal tumor.
- Successful resection of a cavernous hemangioma involving the rectal muscularis propria layer by endoscopic full-thickness resection.
- The impact of the Hedgehog signal pathway on the tumor immune microenvironment of gastric adenocarcinoma by integrated analysis of scRNA-seq and RNA-seq datasets.
- Active Eradication of Helicobacter pylori Within Organized Massive Screening Might Improve Survival of Gastric Cancer Patients.
- Krukenberg tumors metastasized from a T1a gastric carcinoma.
- The potential role of artificial intelligence besides predicting gastric cancer invasion depth.
- Discussion on the common controversies of Helicobacter pylori infection.
- Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects.
- The investigation of volatile organic compounds in diagnosing (early) esophageal squamous cell carcinoma and gastric adenocarcinoma.
- Carrot and carotene and multiple health outcomes: an umbrella review of the evidence.
- Association between nut consumption and cancer risk: a meta-analysis.
- Prognostic role of pretreatment skeletal muscle index in gastric cancer patients: A meta-analysis.
- Whether preferences of gastric cancer patients after surgery for follow-up change over time? Analysis based on discrete choice experiment.
- A Gastrectomy for early-stage gastric cancer patients with or without preserving celiac branches of vagus nerves: A meta-analysis.
- Optimal timing of surgery for gastric cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis.
- Clinical significance of tumor deposits in gastric cancer after radical gastrectomy: a propensity score matching study.
- Does endoscopic submucosal dissection have its place in the treatment of patients with gastric mucosa associated lymphoid tissue lymphoma localized disease after eradication?
- Partial response of metastatic cardia neuroendocrine carcinoma with the combined therapy involving PD-1 blockade after failed multi-line chemotherapies: a case report and literature review.
- Clinicopathological characteristics and survival outcomes of patients with gallbladder neuroendocrine tumor.
- Surgical replays-assisted diagnosis of duodenal stump fistula after laparoscopic radical distal gastrectomy (with video).
- Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials.
- Design, synthesis and biological evaluation of a series of novel pyrrolo[2,3-d]pyrimidin/pyrazolo[3,4-d]pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer.
- Dissecting the genetic and microenvironmental factors of gastric tumorigenesis in mice.
- Effects of EN combined with PN enriched with n-3 polyunsaturated fatty acids on immune related indicators and early rehabilitation of patients with gastric cancer: A randomized controlled trial.
- Feasibility of 3-dimensional-printed model assisting endoscopic resection of gastrointestinal submucosal tumors.
- Metastasis Prevalence and Survival of Patients with T1-2 Gastric Neuroendocrine Tumor Treated with Endoscopic Therapy and Surgery.
- Letter comments on: D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian gastric cancer study group D1 versus D2 randomised controlled trial.
- Development of the PERI-Gastric (PEritoneal Recurrence Index) and PERI-Gram (Peritoneal Recurrence Index NomoGRAM) for predicting the risk of metachronous peritoneal carcinomatosis after gastrectomy with curative intent for gastric cancer:
- What is the clinical value of prediction models in the management of gastric cancer?
- Identifying Diagnostic and Prognostic Differentially Expressed Genes of Gastric Cancer Based on Bioinformatics Analyses of RNA-seq Data.
- Association of recurrent APOBEC3B alterations with the prognosis of gastric-type cervical adenocarcinoma.
- A commentary on "Safety and effectiveness of overlap esophagojejunostomy in totally laparoscopic total gastrectomy for gastric cancer: A systematic review and meta-analysis" (Int J Surg 2022; 102: 106684).
- A commentary on "Uncut Roux-en-Y might reduce the rate of reflux gastritis after radical distal gastrectomy: An evidence mapping from a systematic review" (Int J Surg 2022;97:106184).
- Application of artificial intelligence in the endoscopic diagnosis of early gastric cancer, atrophic gastritis, and Helicobacter pylori infection.
- Genetically predicted testosterone and cancers risk in men: a two-sample Mendelian randomization study.
- Clinical significance of lower perigastric lymph nodes dissection in Siewert type II/III adenocarcinoma of esophagogastric junction: a retrospective propensity score matched study.
- Immunological Perspective: Helicobacter pylori Infection and Gastritis.
- Multifactorial co-exposure within family of gastric cancer: increased risk of familial gastric cancer and tailored prevention.
- Deep learning-based AI model for signet-ring cell carcinoma diagnosis and chemotherapy response prediction in gastric cancer.
- Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report.
- Spicy Food and Chili Peppers and Multiple Health Outcomes: Umbrella Review.
- Effects of Preoperative Oral Nutritional Supplements on Improving Postoperative Early Enteral Feeding Intolerance and Short-Term Prognosis for Gastric Cancer: A Prospective, Single-Center, Single-Blind, Randomized Controlled Trial.
- Efficacy of early enteral nutrition versus total parenteral nutrition for patients with gastric cancer complicated with diabetes mellitus: A systematic review and meta-analysis.
- Helicobacter Pylori Related Gastric Cancer Screening and Cost-Effectiveness Analysis: A Hospital-Based Cross-Sectional Study (SIGES).
- The 'reversibility' of chronic atrophic gastritis after the eradication of Helicobacter pylori.
- Comparison of effectiveness and safety between endoscopic and surgical resection for 2-5 cm gastric stromal tumors.
- Artificial intelligence for diagnosing gastric lesions under white-light endoscopy.
- Assessment of indocyanine green fluorescence lymphography on lymphadenectomy during minimally invasive gastric cancer surgery: a systematic review and meta-analysis.
- Tibetan Ethnicity, Birthplace, Helicobacter pylori Infection, and Gastric Cancer Risk.
- Correlation of Autoimmune Pancreatitis and Risk of Gastric Cancer in East Asian Population.
- Comment on: Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery.
- Comment on: Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinoma.
- Effectiveness and safety of robotic gastrectomy versus laparoscopic gastrectomy for gastric cancer: a meta-analysis of 12,401 gastric cancer patients.
- Propensity score matching analysis for outcomes of laparoscopic versus open caudate lobectomy.
- Prognostic Score System Using Preoperative Inflammatory, Nutritional and Tumor Markers to Predict Prognosis for Gastric Cancer: A Two-Center Cohort Study.
- Development and validation of RNA binding protein-applied prediction model for gastric cancer.
- Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: a case report.
- The long-term survival outcomes of gastric cancer patients with total intravenous anesthesia or inhalation anesthesia: a single-center retrospective cohort study.
- Mixed adenoneuroendocrine carcinomas of stomach and ampulla of vater after curative-intent resection: a single center cases series.
- Long-term endoscopic submucosal dissection with postoperative lung injury: a case report.
- Laparoscopic infrapyloric lymph nodes dissection through the right bursa omentalis approach for gastric cancer.
- Comparative efficacy and safety of anti-HGF/MET pathway agents plus chemotherapy versus chemotherapy alone as first-line treatment in advanced gastric cancer: a protocol for a systematic review and meta-analysis.
- Impact of Surgical Margin Status on Survival in Gastric Cancer: A Systematic Review and Meta-Analysis.
- Associations between hepatitis B virus exposure and the risk of extrahepatic digestive system cancers: A hospital-based, case-control study (SIGES).
- Gastric neoplasm: Gastrointestinal stromal tumor mimicking gastric carcinoma.
- The Impact of Nerve Involvement on the Prognosis of Gastric Cancer Patients with Curative Gastrectomy: An International Multicenter Analysis.
- Successful endoscopic submucosal dissection of a large juvenile polyp in the stomach of an infant.
- Applying immune-related lncRNA pairs to construct a prognostic signature and predict the immune landscape of stomach adenocarcinoma.
- Tomato and lycopene and multiple health outcomes: Umbrella review.
- Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
- Chronic inflammation and long-lasting changes in the gastric mucosa after Helicobacter pylori infection involved in gastric cancer.
- Taxifolin suppresses the malignant progression of gastric cancer by regulating the AhR/CYP1A1 signaling pathway.
- Gastrectomy with omentum preservation versus gastrectomy with omentectomy for locally advanced gastric cancer: A systematic review and meta-analysis.
- Monomorphic Epitheliotropic Intestinal T-cell Lymphoma of the Stomach: Two Case Reports and a Literature Review.
- Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
- The log odds of negative lymph nodes/T stage: a new prognostic and predictive tool for resected gastric cancer patients.
- Inflammatory bowel disease and risk of gastric, small bowel and colorectal cancer: a meta-analysis of 26 observational studies.
- Comparisons of perioperative and survival outcomes of laparoscopic versus open gastrectomy for serosa-positive (pT4a) gastric cancer patients: a propensity score matched analysis.
- Closure of Petersen's defect in gastrectomy for gastric cancer: an interrupted time series analysis from a high-volume institution in China.
- The value of spleen-preserving lymphadenectomy in total gastrectomy for gastric and esophagogastric junctional adenocarcinomas: A long-term retrospective propensity score match study from a high-volume institution in China.
- Application of clockwise modularized laparoscopic lymphadenectomy in the suprapancreatic area, a propensity score matching study and comparison with open gastrectomy.
- Incidence of adhesive small bowel obstruction after gastrectomy for gastric cancer and its risk factors: a long-term retrospective cohort study from a high-volume institution in China.
- Low level of microsatellite instability correlates with short disease-free survival of gastric cancer patients undergoing neoadjuvant chemotherapy.
- The Effectiveness of Postoperative Chemotherapy on pT1bN0 and pT2N0 Gastric Cancer Patients with Risk Factors: An International Dual-Center Analysis.
中文论文(未计入)18
- [Current status and trends of perioperative immunotherapy for gastric cancer].
- [Exploration of the lymph node dissection range and strategies for adenocarcinoma of esophagogastric junction from the perspective of membrane anatomy].
- [Application and clinical significance of the "Four-Step Procedure" of laparoscopic exploration in the diagnosis of gastric cancer with peritoneal metastasis].
- [Prudent promotion of new surgical techniques for functional preservation of gastric cancer].
- [Network Pharmacology Study of Compound Ligustrazine in Gastric Cancer Therapy].
- [Thinking about the extent and technique of lower mediastinal lymph nodes dissection for adenocarcinoma of esophagogastric junction].
- [Safety of patients undergoing radical resection combined with paclitaxel-based hyperthermic intraperitoneal chemotherapy for locally advanced gastric cancer].
- [Interpretation of Chinese expert consensus on the surgical treatment for adenocarcinoma of esophagogastric junction(2024 edition)].
- [Analysis and Treatment Experience of 25 Cases of Primary Gastric Lymphoma with Acute Upper Gastrointestinal Bleeding as the Primary Manifestation].
- [Clinical Value of White Light Image, Endoscopic Ultrasonography and Magnifying Endoscopy with Narrow Band Imaging in Evaluation of Indications for Endoscopic Treatment of Early Gastric Cancer].
- [Comparison of postoperative mid-term and long-term quality of life between Billroth-I gastroduodenostomy and Billroth-II gastrojejunostomy after radical distal gastrectomy in patients with gastric cancer: a cohort study based on a case reg
- [How to master the clinical study on digestive tract reconstruction in gastric cancer surgery].
- [Clinical significance of No.11p posterior lymph nodes dissection in gastric cancer surgery].
- [Treatment of Siewert type II adenocarcinoma of the esophagogastric junction: the perspectives from thoracic surgery].
- [MiR-4484 regulates the expression of integrin α 6 in gastric cancer tissues and its significance].
- [Utilizing Academic Clubs to Foster Practical Research Ability of Medical Students-Volunteer Team of Gastric Cancer Surgery of West China Hospital, Sichuan University].
- [Current status of diagnosis and treatment of gastric cancer peritoneal metastasis].
- [Risk factors of postoperative pulmonary infection of gastric cancer and perioperative intervention measures].
它在 ClinicalTrials.gov 上的全部试验(任何状态)51
- XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
- CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
- Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer
- General Tissue Response Classification System After Chemotherapy
- Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
- Systematic Review and Meta-analysis of Cereal or Grain Consumption and Gastric Cancer
- Prospective Study on Double-Stapling End-to-End Gastroduodenostomy Billroth-I Anastomosis in Laparoscopy-Assisted Surgery for Locally Advanced Distal Gastric Cancers
- CT Radiomics and Deep Learning-Based Non-Invasive Model for Tracing Primary Sites of Adenocarcinoma Liver Metastases: Automatic Differentiation of Multiple Primary Digestive Tumors
- Length of the Proximal Resection Margin for Siewert-II/Siewert-III Tumors
- Povidone-iodine and the Normal Saline Cleaning the Incision for the SSIs
- Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery
- Roux-en-Y vs. Roux-en-Y+ Pouch for D2 Total Gastrectomy
- Impact of Gastric Tube Reconstruction Widths on Quality of Life for Esophagogastric Cancers
- Non-surgical Management After NIT for dMMR/MSI-H GC
- Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma
- Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.
- Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
- Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
- EpCAM CAR-T for Treatment of Advanced Solid Tumors
- Effect of Obesity on Surgical Outcomes and Survival for Gastric Cancer
- Double Tract Anastomosis and Gastric Tube Anastomosis to Proximal Gastrectomy
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD
- Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
- A Phase 2 Clinical Study of ABSK061 and ABSK043
- A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
- A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
- Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
- A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
- A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
- Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
- A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
- A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
- Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer
- Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer
- Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- Study of Metatinib Tromethamine Tablet
- A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
- Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
- Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)
癌症
肝母细胞瘤
Hepatoblastoma2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 2.6%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 4 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。
这些数字背后的记录
牵头的论文4
- β-Catenin regulates distinct pathways from YAP and suppresses ONECUT1 to drive hepatoblastoma development in mice and humans.
- Incidence and trends of hepatic cancer among children and adolescents in the United States from 2000 to 2017: Evidence from the Surveillance, Epidemiology, and End Results registry data.
- MRI-based deep learning model for differentiation of hepatic hemangioma and hepatoblastoma in early infancy.
- SOCS2 inhibits hepatoblastoma metastasis via downregulation of the JAK2/STAT5 signal pathway.
早期论文(2016–2020 年)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 3 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
癌症
脊索瘤
Chordoma2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 2.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 4 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。
这些数字背后的记录
牵头的论文3
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 36 篇,占 1.6%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 13 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
牵头的论文36
- KC1036, a multi-kinase inhibitor with anti-angiogenic activity, can effectively suppress the tumor growth of Ewing sarcoma.
- Reactivating P53 to treat osteosarcoma: A tetrahedral framework nucleic acids-based approach.
- Sono-activable and biocatalytic 3D-printed scaffolds for intelligently sequential therapies in osteosarcoma eradication and defect regeneration.
- 3D-Printed Metacarpal Prosthesis in the Treatment of Primary Osteosarcoma of the First Metacarpal: A Novel Surgical Technique.
- 3D-Printed Talus-Calcaneus Prosthesis in Treating Ewing's Sarcoma: A Case Report.
- Tetrahedral Framework Nucleic Acid-Loaded Retinoic Acid Promotes Osteosarcoma Stem Cell Clearance.
- Tumor-oriented and chemo-photothermal nanoplatform capable of sensitizing chemotherapy and ferroptosis against osteosarcoma metastasis.
- Advancements in Photothermal Therapy Using Near-Infrared Light for Bone Tumors.
- Quality assessment of online osteosarcoma-related videos in Mainland China: A cross-sectional study.
- Surgical Treatment of Osteosarcoma Induced Distant Pre-Metastatic Niche in Lung to Facilitate the Colonization of Circulating Tumor Cells.
- Primary hepatic carcinosarcoma with osteosarcoma components: A case report and literature review.
- Bibliometric analysis of Ewing sarcoma from 1993 to 2022.
- Thiram, an inhibitor of 11ß-hydroxysteroid dehydrogenase type 2, enhances the inhibitory effects of hydrocortisone in the treatment of osteosarcoma through Wnt/β-catenin pathway.
- Advances of Osteosarcoma Models for Drug Discovery and Precision Medicine.
- The clinical characteristics, novel predictive tool, and risk classification system for primary Ewing sarcoma patients that underwent chemotherapy: A large population-based retrospective cohort study.
- Transformation of Cemento-Ossifying Fibroma into Osteosarcoma after Radiotherapy and Nine Endoscopic Surgeries.
- MiR-30 Family: A Novel Avenue for Treating Bone and Joint Diseases?
- Rare origin - Ewing's sarcoma of the pleura: a case report and literature review.
- Comment on: Membrane-type 1 matrix metalloproteinase as predictor of survival and candidate therapeutic target in Ewing sarcoma.
- Diagnostic value of MDM2 RNA in situ hybridization for low-grade osteosarcoma: Consistency comparison of RNA in situ hybridization, fluorescence in situ hybridization, and immunohistochemistry.
- Synchronous lung and multiple soft tissue metastases developed from osteosarcoma of tibia: a rare case report and genetic profile analysis.
- Primary Ewing sarcoma/peripheral primitive neuroectodermal tumors in the cranial bone and mobile spine: what is the difference?
- Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential.
- Hematological Prognostic Scoring System Can Predict Overall Survival and Can Indicate Response to Immunotherapy in Patients With Osteosarcoma.
- Characteristics and prognosis of primary pulmonary osteosarcoma: a pooled analysis.
- Nanoengineering a metal-organic framework for osteosarcoma chemo-immunotherapy by modulating indoleamine-2,3-dioxygenase and myeloid-derived suppressor cells.
- Use of Nomogram on Nutritional Assessment Indicators to Predict Clinical Outcomes in Patients Undergoing Surgical Resection for High-Grade Osteosarcoma.
- 3D Customized Biological Tibial Intramedullary Nail Fixation for the Treatment of Fracture after Massive Allograft Bone Transplantation of Tibial Osteosarcoma: A Case Report.
- The safety and efficiency of photodynamic therapy for the treatment of osteosarcoma: A systematic review of in vitro experiment and animal model reports.
- Primary Osteosarcoma of Left Atrial Appendage in a Patient with Rheumatic Heart Disease.
- A huge Ewing's sarcoma of the rib presenting with superior vena cava syndrome and dysphagia.
- 3D-Printed Multifunctional Polyetheretherketone Bone Scaffold for Multimodal Treatment of Osteosarcoma and Osteomyelitis.
- 3D Printed Multifunctional Ti6Al4V-Based Hybrid Scaffold for the Management of Osteosarcoma.
- Progress of Phototherapy Applications in the Treatment of Bone Cancer.
- Mitochondria-targeting graphene oxide nanocomposites for fluorescence imaging-guided synergistic phototherapy of drug-resistant osteosarcoma.
- Askin tumor in the chest wall.
中文论文(未计入)2
早期论文(2016–2020 年)22
- PTEN in osteosarcoma: Recent advances and the therapeutic potential.
- Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.
- Knockdown of Ski decreases osteosarcoma cell proliferation and migration by suppressing the PI3K/Akt signaling pathway.
- A nomogram for predicting cancer-specific survival in patients with osteosarcoma as secondary malignancy.
- RRAS2 knockdown suppresses osteosarcoma progression by inactivating the MEK/ERK signaling pathway.
- Diosgenin exerts its tumor suppressive function via inhibition of Cdc20 in osteosarcoma cells.
- Nifuroxazide induces apoptosis, inhibits cell migration and invasion in osteosarcoma.
- Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.
- SP1-induced upregulation of long non-coding RNA HCP5 promotes the development of osteosarcoma.
- Total ulna replacement with a 3D-printed custom-made prosthesis after en bloc tumor resection: A case report.
- Amplification of FRS2 in atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma: a clinicopathological and genetic study of 146 cases.
- [Therapeutic Effect of Uncemented Allograft-prosthetic Composite for the Reconstruction of Tumorous Bone Defect].
- Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis.
- Uncemented three-dimensional-printed prosthetic reconstruction for massive bone defects of the proximal tibia.
- Integrated bioinformatics analysis of miRNA expression in osteosarcoma.
- Successful removal of giant primary osteosarcoma in the anterior mediastinum invading the superior vena cava and right lung with artificial blood vessel reconstruction.
- Primary Left Atrial Osteosarcoma.
- A multi-level comparative analysis of human femoral cortical bone quality in healthy cadavers and surgical safe margin of osteosarcoma patients.
- A case report of apatinib in treating osteosarcoma with pulmonary metastases.
- Antidifferentiation Noncoding RNA Regulates the Proliferation of Osteosarcoma Cells.
- A rare case of extensive primary meningeal osteosarcoma in childhood.
- Congenital Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor: A Case Report and Review of the Literature.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 33 篇,占 6.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
成都有 6 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- 分期
- II/III期
- 开始
- 2026-05
- 登记号
- NCT07379047
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文33
- Development and validation of CT-based nomograms for predicting recurrence and prognosis in gastrointestinal stromal tumor.
- NF1 Mutated Gastrointestinal Stromal Tumors With Coamplification of MDM2 and MYC.
- Clinicopathological analysis of anti-VEGF drug-associated renal thrombotic microangiopathy: A case series and review of the literature.
- Prognostic factors for metastatic gastrointestinal stromal tumors treated with cytoreductive surgery: a retrospective cohort study.
- The feasibility and safety of laparoscopic limited resection for duodenal gastrointestinal stromal tumor: a propensity score-matched analysis.
- FDG PET/CT Image of Extragastrointestinal Stromal Tumor in the Posterior Mediastinum.
- Gastrointestinal stromal tumors regulate macrophage M2 polarization through the MIF/CXCR4 axis to immune escape.
- Analysis of the diagnostic value of CT radiomics models in differentiating GIST and other mesenchymal tumors.
- Wild-type gastrointestinal stromal tumors with NTRK gene fusions: A clinicopathological study.
- Surgical treatment of the metastatic gastrointestinal stromal tumor after resistance to available tyrosine kinase inhibitors: A case report.
- Clinicopathological and mutational characteristics of primary double mutant gastrointestinal stromal tumor: a single center study with review of the literature.
- Efficacy of post-first-line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta-analysis.
- Impact of surgical resection for gastrointestinal stromal tumor (GIST) patients with initially diagnosed synchronous hepatic metastases on long-term survival outcomes.
- DOG1 as a novel antibody-drug conjugate target for the treatment of multiple gastrointestinal tumors and liver metastasis.
- Two-staged hepatectomy for bilobar metastases of the gastrointestinal stromal tumor (GIST).
- Primary hepatic gastrointestinal stromal tumor: A case series.
- Open and minimally invasive surgery for gastrointestinal stromal tumours: a systematic review and network meta-analysis protocol.
- The KDM6A-SPARCL1 axis blocks metastasis and regulates the tumour microenvironment of gastrointestinal stromal tumours by inhibiting the nuclear translocation of p65.
- Development and external validation of a nomogram for individualized adjuvant imatinib duration for high-risk gastrointestinal stromal tumors: A multicenter retrospective cohort study.
- Feasibility of 3-dimensional-printed model assisting endoscopic resection of gastrointestinal submucosal tumors.
- Cap-assisted endoscopic full-thickness resection for small gastrointestinal stromal tumors.
- Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study.
- Surgical strategies for duodenal gastrointestinal stromal tumors.
- Comparison of effectiveness and safety between endoscopic and surgical resection for 2-5 cm gastric stromal tumors.
- Prognostic significance of hemoglobin, albumin, lymphocyte, platelet in gastrointestinal stromal tumors: A propensity matched retrospective cohort study.
- Use of computed tomography for distinguishing heterotopic pancreas from gastrointestinal stromal tumor and leiomyoma.
- Primary retroperitoneal gastrointestinal stromal tumor mimicking adrenal mass: A case report.
- Clinicopathological features, clinical efficacy on 101 cases of rectal gastrointestinal stromal tumors, and the significance of neoadjuvant therapy.
- Integrated analysis of long non-coding RNAs and mRNAs associated with malignant transformation of gastrointestinal stromal tumors.
- Gastric neoplasm: Gastrointestinal stromal tumor mimicking gastric carcinoma.
- Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review.
- Surgical resection for patients with recurrent or metastatic gastrointestinal stromal tumors: a protocol for a systematic review and meta-analysis update.
- Transperineal core-needle biopsy of a rectal subepithelial lesion guided by endorectal ultrasound after contrast-enhanced ultrasound: A case report.
中文论文(未计入)2
早期论文(2016–2020 年)28
- Current and Potential Applications of Artificial Intelligence in Gastrointestinal Stromal Tumor Imaging.
- Identification of gastrointestinal stromal tumors from leiomyomas in the esophagogastric junction: A single-center review of 136 cases.
- Preoperative imatinib treatment in patients with locally advanced and metastatic/recurrent gastrointestinal stromal tumors: A single-center analysis.
- [Efficacy of Transcatheter Embolization for Gastrointestinal Stromal Tumor with Gastrointestinal Hemorrhage in 17 Cases].
- Long-term survival among patients with gastrointestinal stromal tumors diagnosed after another malignancy: a SEER population-based study.
- [Clinical diagnosis and treatment of gastrointestinal stromal tumor: matching technological breakthrough with patient care].
- Endoscopic full-thickness resection for a duodenal gastrointestinal stromal tumour.
- PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
- Primary Gastrointestinal Stromal Tumor of the Liver.
- Diffuse ileal ganglioneuromatosis mimicking a gastrointestinal stromal tumor: A case report.
- Primary hepatic gastrointestinal stromal tumor with right adrenal gland invasion: A case report and systematic literature review.
- Tenascin-C expression is significantly associated with the progression and prognosis in gastric GISTs.
- Proteomic Maps of Human Gastrointestinal Stromal Tumor Subgroups.
- Association between CT imaging features and KIT mutations in small intestinal gastrointestinal stromal tumors.
- [Real world study and its application in gastrointestinal stromal tumor].
- Secreted protein acidic and rich in cysteine-like 1 suppresses metastasis in gastric stromal tumors.
- Role of surgical resection for patients with recurrent or metastatic gastrointestinal stromal tumors: A systematic review and meta-analysis.
- Comparison Analysis of Three Different Types of Minimally Invasive Procedures for Gastrointestinal Stromal Tumors ≤5 cm.
- Effect of Gastrointestinal Bleeding on Gastrointestinal Stromal Tumor Patients: A Retrospective Cohort Study.
- Giant gastric stromal tumor mimicking as a posterior mediastinal mass: A case report and literature review.
- Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib: A retrospective cohort study.
- Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study.
- [Associations of Preoperative Platelet-to-lymphocyte Ratio and Derived Neutrophil-to-lymphocyte Ratio with thePrognosis of Gastrointestinal Stromal Tumor].
- [FAP Expression and Its Association with the Prognosis of Gastric Stromal Tumors].
- Laparoscopic Versus Open Resection for Gastric Gastrointestinal Stromal Tumors (GISTs): A Size-Location-Matched Case-Control Study.
- Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).
- A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment.
- [Preliminary understanding of gastrointestinal stromal tumor with the highest risk].
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
- Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
- A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
- A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.4%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 8 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma
- 分期
- 早期I期
- 开始
- 2026-07
- 登记号
- NCT07767630
年龄 1 岁 至 100 岁(登记的条件)
牵头:四川大学华西医院成都
- 正在招募Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma
- 分期
- 早期I期
- 开始
- 2025-07
- 登记号
- NCT07067346
年龄 12 个月 至 未注明(登记的条件)
牵头:四川大学华西医院成都
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文5
- TSPYL5-driven G3BP1 nuclear membrane translocation facilitates p53 cytoplasm sequestration via accelerating RanBP2-mediated p53 sumoylation and nuclear export in neuroblastoma.
- The Complementary Role of 68 Ga-FAPI-04 PET/CT in a Case of Neuroblastoma.
- Contrast computed tomography-based radiomics is correlation with COG risk stratification of neuroblastoma.
- Extracellular matrix stiffness controls VEGF165 secretion and neuroblastoma angiogenesis via the YAP/RUNX2/SRSF1 axis.
- Hyperthermia in a pediatric patient with neuroblastoma during anesthesia: a case report.
早期论文(2016–2020 年)5
- The Inhibitory Effect of Carboplatin Injection on Human Neuroblastoma SK-N-SH.
- Primary orbital ganglioneuroblastoma in a child: A case report.
- The effect of age distribution on the prognosis of retroperitoneal neuroblastoma.
- Impact of extent of resection on survival in high-risk neuroblastoma: A systematic review and meta-analysis.
- Primary cervical ganglioneuroblastoma: A case report.
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 9 篇,占 5.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 2 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。
这些数字背后的记录
牵头的论文9
- KC1036, a multi-kinase inhibitor with anti-angiogenic activity, can effectively suppress the tumor growth of Ewing sarcoma.
- 3D-Printed Talus-Calcaneus Prosthesis in Treating Ewing's Sarcoma: A Case Report.
- Bibliometric analysis of Ewing sarcoma from 1993 to 2022.
- The clinical characteristics, novel predictive tool, and risk classification system for primary Ewing sarcoma patients that underwent chemotherapy: A large population-based retrospective cohort study.
- Rare origin - Ewing's sarcoma of the pleura: a case report and literature review.
- Comment on: Membrane-type 1 matrix metalloproteinase as predictor of survival and candidate therapeutic target in Ewing sarcoma.
- Primary Ewing sarcoma/peripheral primitive neuroectodermal tumors in the cranial bone and mobile spine: what is the difference?
- A huge Ewing's sarcoma of the rib presenting with superior vena cava syndrome and dysphagia.
- Askin tumor in the chest wall.
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 59 篇,占 3.5%。
- 牵头的开放试验
- 0
- 正在或即将招募
成都有 2 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 5
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
- 分期
- I期
- 开始
- 2026-03
- 登记号
- NCT07255898
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心成都
- 正在招募A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
- 分期
- I期
- 开始
- 2024-08
- 登记号
- NCT06484777
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心成都
- 正在招募Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- 分期
- I/II期
- 开始
- 2024-03
- 登记号
- NCT06484829
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心成都
- 正在招募A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
- 分期
- I期
- 开始
- 2024-11
- 登记号
- NCT06700395
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、成都
- 正在招募A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- 分期
- IV期
- 开始
- 2022-03
- 登记号
- NCT05201781
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南京、广州、成都、杭州、福州、西安
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文59
- Single-cell RNA sequencing reveals immune regulatory mechanisms and molecular therapeutic strategies in the microenvironment of multiple myeloma.
- Cost-effectiveness analysis of daratumumab plus bortezomib, melphalan and prednisone versus bortezomib, melphalan and prednisone in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation.
- LncRNA HCG11 regulates selinexor sensitivity in multiple myeloma.
- The mitochondrial protease ClpP is a promising target for multiple myeloma treatment.
- A disulfidptosis-related gene signature predicts prognosis and immune-metabolic landscape in multiple myeloma.
- Incidence, Clinical Features, and Prognostic Value of New-Onset Renal Impairment in Multiple Myeloma.
- Navigating the Prognostic Complexity of IgH Cytogenetic Abnormalities in Multiple Myeloma Among Diverse IgH Cytogenetic Abnormalities-Involved High-Risk Stratifications.
- Bortezomib enhances the efficacy of BCMA CAR-T therapy through up-regulating BCMA expression in myeloma cells.
- Beneficial effects of aerobic exercises on multiple myeloma: Mechanisms and clinical observations.
- A comprehensive analysis of bone marrow-derived cytogenetic abnormalities in multiple myeloma patients with extramedullary disease.
- Impact of integrated nursing care on rehabilitation process of inpatients with multiple myeloma in an academic hematology department.
- Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma.
- Decreased RNA-binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide.
- Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma.
- RNA-binding protein hnRNPU regulates multiple myeloma resistance to selinexor.
- A predictive risk-scoring model for survival prognosis of multiple myeloma based on gain/amplification of 1q21: Experience in a tertiary hospital in South-Western China.
- Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma.
- Dihydrolipoamide dehydrogenase (DLD) is a novel molecular target of bortezomib.
- Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era.
- Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs.
- CAR-T Therapy in Relapsed Refractory Multiple Myeloma.
- Clinical significance of T helper cell subsets in the peripheral blood and bone marrow of patients with multiple myeloma.
- Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials.
- BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma.
- Multiple myeloma: signaling pathways and targeted therapy.
- Development of a cell adhesion-based prognostic model for multiple myeloma: Insights into chemotherapy response and potential reversal of adhesion effects.
- Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma.
- Single-cell sequencing reveals the correlation of aggrephagy signaling and multiple myeloma immune microenvironment composition.
- Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma.
- Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment.
- BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
- Low cholesterol levels are associated with increasing risk of plasma cell neoplasm: A UK biobank cohort study.
- Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma.
- A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma.
- Hypermetabolic Subserosal Uterine Leiomyoma With Synchronous Atypical Multiple Myeloma Mimicking Ovarian Malignancy With Multiple Bone Metastases on 18F-FDG PET/CT.
- Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects.
- Case report: Vesiculobullous eruption with an atypical IgA deposition pattern in a patient with multiple myeloma-A case report and literature review.
- Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis.
- A systematic review on performance analysis of critical time points in multiple myeloma treated by CAR-T cell immunotherapy.
- Methylcrotonyl-CoA carboxylase subunit 1 (MCCA) regulates multidrug resistance in multiple myeloma.
- Nutritional Status Indices and Monoclonal Gammopathy of Undetermined Significance Risk in the Elderly Population: Findings from the National Health and Nutrition Examination Survey.
- Body Mass Index and Cancer Risk: An Umbrella Review of Meta-Analyses of Observational Studies.
- Cancer-Cell-Biomimetic Nanoparticles for Targeted Therapy of Multiple Myeloma Based on Bone Marrow Homing.
- ALCAM regulates multiple myeloma chemoresistant side population.
- Site-specific N-glycosylation characterization of micro monoclonal immunoglobulins based on EThcD-sceHCD-MS/MS.
- False positive results: a challenge for laboratory physicians and hematologists in treating multiple myeloma with daratumumab.
- ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.
- Estrogen-Responsive Gene MAST4 Regulates Myeloma Bone Disease.
- FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma.
- Symptom clusters and quality of life in ambulatory patients with multiple myeloma.
- Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy.
- Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomise
- Extramedullary intracardiac multiple myeloma misdiagnosed as a thrombus: a case report.
- BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions.
- Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma.
- Multiple Myeloma Presenting as Disseminated Osteoblastic Lesions With Intense 18F-FDG Uptake on PET/CT.
- Predictive Values of PET/CT in Combination With Regulatory B Cells for Therapeutic Response and Survival in Contemporary Patients With Newly Diagnosed Multiple Myeloma.
- Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its Inhibitor.
- Bortezomib-based regimens improve the prognosis of newly diagnosed MM patients with chromosomal aberrations except for del(17q13): A retrospective study from a single center.
中文论文(未计入)5
- [Advances in Modeling of Multiple Myeloma in Mice].
- [Progress in Chimeric Antigen Receptor-Modified Natural Killer Cells for Multiple Myeloma].
- [Receptor Activator of Nuclear Factor κB Ligand-Receptor Activator of Nuclear Factor κB Signaling Pathway in Myeloma Bone Disease].
- [Full-cycle Health Management of Multiple Myeloma].
- [Efficacy and safety of daratumumab in patients with relapsed/refractory multiple myeloma].
它在 ClinicalTrials.gov 上的全部试验(任何状态)21
- CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma
- Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
- A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
- A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
- A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
- Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- A Study of Daratumumab
- A Study of NINLARO® in Chinese Adults With Multiple Myeloma
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Ninlaro in Real World Clinical Practice in China
- A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule
- A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
- A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
- Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
血液疾病
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头的开放试验
- 0
- 正在或即将招募
成都有 2 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- 分期
- 未注明
- 开始
- 2024-06
- 登记号
- NCT06450067
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、天津、广州、徐州、成都、武汉、济南、郑州
- 正在招募Phase Ib Clinical Study of Keynatinib
- 分期
- I期
- 开始
- 2020-09
- 登记号
- NCT04807881
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、北京、成都
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL
- Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- Phase Ib Clinical Study of Keynatinib
- Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
血液疾病
再生障碍性贫血
Aplastic anaemia2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 2 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。
这些数字背后的记录
牵头的论文4
- The diagnostic value and clinical correlations of bone marrow supernatant S100A8 and S100A9 in myelodysplastic neoplasms.
- Diagnosis and Management of Fanconi Anemia.
- Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia.
- Umbilical cord-derived mesenchymal stem cells cultured in the MCL medium for aplastic anemia therapy.
血液疾病
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 12 篇,占 3.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 3 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。
这些数字背后的记录
牵头的论文12
- Flow cytometric analysis of the immune cell subsets in adult hemophagocytic lymphohistiocytosis.
- Prognostic role of prognostic nutritional index in patients with lymphoma-associated hemophagocytic lymphohistiocytosis.
- Intravascular large B-cell lymphoma as a covert trigger for hemophagocytic lymphohistiocytosis complicated with capillary leak syndrome: a case report and literature review.
- Sulfasalazine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) coinfected with COVID-19 complicated by hemophagocytic lymphohistiocytosis: a case report.
- Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms.
- Chronic active Epstein-Barr virus infection involving gastrointestinal tract with hemophagocytic lymphohistiocytosis.
- The predictive value of hematological inflammatory markers for acute kidney injury and mortality in adults with hemophagocytic Lymphohistiocytosis: A retrospective analysis of 585 patients.
- A prediction model for acute kidney injury in adult patients with hemophagocytic lymphohistiocytosis.
- Epstein-Barr Virus-Positive Lymphoma-Associated Hemophagocytic Syndrome: A Retrospective, Single-Center Study of 51 Patients.
- Lymphoma-associated hemophagocytic syndrome: a retrospective study from a single center.
- Clinical features and prognostic factors of acute kidney injury caused by adult secondary hemophagocytic lymphohistiocytosis.
- Case Report: Visceral Leishmaniasis-associated Hemophagocytic Lymphohistiocytosis in Adults: A Case Series and Literature Review.
PubMed 以外找到的论文(未计入)18
- Dual anti-HLH and antitumor efficacy of golidocitinib in relapsed/refractory PTCL-associated hemophagocytic lymphohistiocytosis: A retrospective safety and activity analysis
- Effects of golidocitinib and gecacitinib in mouse models of primary and secondary hemophagocytic lymphohistiocytosis
- Erythrocyte membrane-camouflaged JAK1 inhibitor for the treatment of hemophagocytic lymphohistiocytosis
- Real-world safety profile of PD-1 inhibitors in Epstein–Barr Virus–Associated lymphoproliferative disorders: A retrospective analysis from west China hospital
- Chronic active EBV infection with hemophagocytic lymphohistiocytosis and progression to aggressive NK cell leukemia
- Clinical Characteristics and Prognosis of Subcutaneous Panniculitis-like T-Cell Lymphoma Based on the SEER Database
- Pharmacological and Mechanism Study of a New RIPK1 Inhibitor Via Necroptosis to Treat Hemophagocytic Lymphohistiocytosis
- Herombopag, a Second Generation Thrombopoietin-Receptor Agonist, Stimulates Platelet Engraftment after Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation
- Additional file 2 of NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis
- Clinical Characteristics of Hemophagocytic Lymphohistiocytosis in Adults with Central Nervous System Involvement
- Familial hemophagocytic lymphohistiocytosis with Epstein–Barr virus infection and progression to aggressive NK-cell leukemia: a case report and review of the literature
- Flonoltinib, a Novel JAK2/FLT3 Inhibitor, Potently Treats Hemophagocytic Lymphohistiocytosis and Increases Sensitivity to Dexamethasone
- Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up
- Risk factors of in-hospital death in pediatric patients with hemophagocytic lymphohistiocytosis: A case-control study
- Risk factors of in-hospital death in pediatric patients with hemophagocytic lymphohistiocytosis: A case-control study
- Chronic active EB virus infection with hemophagocytic lymphohistiocytosis and progression to aggressive NK cell leukemia: a case report and review of the literature
- Development and Initial Validation of a Novel Prognostic Model in Adult Secondary Hemophagocytic Lymphohistiocytosis Patients: Experience From a Single-center Retrospective Study
- MO412THE RISK FACTORS OF ACUTE KIDNEY INJURY CAUSED BY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
血液疾病
β 地中海贫血
Beta thalassaemia2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
成都有 6 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
- 分期
- II期
- 开始
- 2019-11
- 登记号
- NCT04143724
年龄 6 岁 至 17 岁(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心南宁、广州、成都、深圳
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文2
- Case Report: Abnormally Low Glycosylated Hemoglobin A1c Caused by Clinically Silent Rare β-Thalassemia in a Tujia Chinese Woman.
- A Triple-Heterozygous β-Thalassemia Patient Demonstrated an Unusual Electrophoresis Pattern Due to a Novel β0 Mutation [an IVS-II-654 (C>T) mutation with a Hb Zürich-Langstrasse (HBB: c.151A>T) mutation in cis].
早期论文(2016–2020 年)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
血液疾病
血友病 A
Haemophilia A2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 4 篇,占 1.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 6 家医院列在血友病 A下全国有 160 家医院列在血友病 A下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。
这些数字背后的记录
牵头的论文4
- Clinical outcomes of total hip and knee arthroplasty for end-stage hemophilic arthropathy in patients with hemophilia: a retrospective study.
- Perioperative Hematological Outcomes of Simultaneous Double Total Joint Arthroplasty for Hemophilic Arthritis of the Hip and Knee: A Retrospective Study.
- Efficacy and Safety of Adeno-Associated Virus-Based Clinical Gene Therapy for Hemophilia: A Systematic Review and Meta-Analysis.
- Life-threatening bleeding in a patient with pemphigoid-induced acquired hemophilia A and successfully treated with rituximab and rFVIIa: A case report.
早期论文(2016–2020 年)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
血液疾病
血栓性血小板减少性紫癜
Thrombotic thrombocytopenic purpura2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 1 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。
血液疾病
范可尼贫血
Fanconi anaemia2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 2 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。
其他疾病
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 36 篇,占 7.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 2 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。
这些数字背后的记录
牵头的论文36
- Glymphatic dysfunction in neuromyelitis optica spectrum disorder.
- Severe attacks and worse prognosis in patients with late-onset neuromyelitis optica spectrum disorder highlight the need for early highly effective treatment.
- Retinal microvascular differences between multiple sclerosis and neuromyelitis optica spectrum disorder: a cross-sectional study with diagnostic modeling.
- Progressive retinal and microvascular neurodegeneration in neuromyelitis optica spectrum disorders: a longitudinal SS-OCT/OCTA study.
- Serum GFAP and NFL as biomarkers for disease activity, severity and disability in NMOSD.
- A real-world study on the utility of regular rituximab treatment for neuromyelitis optica spectrum disorder.
- Patterns of neuromyelitis optica spectrum disorder attacks in different age groups and sexes depending on the status of immunosuppressive therapy: A retrospective cohort study.
- Case report: Identification of Hepatitis B Virus in the cerebrospinal fluid of neuromyelitis optica spectrum disorders and successful treatment with ofatumumab and inebilizumab.
- Discussion on the Application of Rapid Immunoblot Assay for AQP4-IgG Detection.
- Clinical features and prognosis of Tibetan patients with neuromyelitis optica spectrum disorder are different from those of Han Chinese patients.
- Cytomegalovirus and Epstein-Barr virus infections in patients with neuromyelitis optica spectrum disorder.
- Correlation between severe attacks and serum aquaporin-4 antibody titer in neuromyelitis optica spectrum disorder.
- Initial BMI effects on clinical presentation and prognosis in neuromyelitis optica spectrum disorder.
- COVID-19 and the risk of neuromyelitis optica spectrum disorder: a Mendelian randomization study.
- Visual disability in neuromyelitis optica spectrum disorders: prognostic prediction models.
- Retinal structural and microvascular changes in myelin oligodendrocyte glycoprotein antibody disease and neuromyelitis optica spectrum disorder: An OCT/OCTA study.
- Non-immune system comorbidity in neuromyelitis optica spectrum disorders.
- Serum antinuclear antibodies associate with severe disease activity in neuromyelitis optica spectrum disorder.
- Satralizumab as a treatment for pediatric-onset neuromyelitis optica spectrum disorder with cluster attack: a case report.
- Investigation on marital status of patients with neuromyelitis optica spectrum disorders in China.
- Immune Repertoire Profiling Reveals Its Clinical Application Potential and Triggers for Neuromyelitis Optica Spectrum Disorders.
- Effects of pregnancy on neuromyelitis optica spectrum disorder and predictors of related attacks.
- Brain structural and functional connectivity alterations are associated with fatigue in neuromyelitis optica spectrum disorder.
- Granzyme B in circulating CD8+ T cells as a biomarker of immunotherapy effectiveness and disability in neuromyelitis optica spectrum disorders.
- The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases.
- Clinical Characteristics of Anti-N-Methyl-d-Aspartate Receptor Encephalitis Overlapping with Demyelinating Diseases: A Review.
- Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis.
- Sparser macula microvasculature in neuromyelitis optica spectrum disorder occurs independently of optic neuritis.
- Mortality of neuromyelitis optica spectrum disorders in a Chinese population.
- CD8+ T cell subpopulations and pro-inflammatory cytokines in neuromyelitis optica spectrum disorder.
- The immune regulatory effects of tetrahedral framework nucleic acid on human T cells via the mitogen-activated protein kinase pathway.
- Neuromyelitis Optica Spectrum Disorder With Hyponatremia as an Initial Presentation: A Case Report.
- Psychiatric symptoms as initial manifestation in neuromyelitis optica spectrum disorder without cortical lesions: A report of two cases.
- Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.
- Brain changes correlate with neuropathic pain in patients with neuromyelitis optica spectrum disorders.
- Hemorrhagic encephalitis in a patient with neuromyelitis optica: A case report.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
IgG4相关性疾病
IgG4-related disease2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 11 篇,占 4.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
成都有 2 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
- 分期
- I/II期
- 开始
- 2026-01
- 登记号
- NCT07061938
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、成都、武汉
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文11
- Immunoglobulin G4-related disease with pleural involvement in an 80-year-old female patient: A case report and literature review.
- IgG4-related disease presenting with hypercalcemia: case report and mechanistic insights.
- Case Report: IgG4-RD-related ophthalmopathy combined with monoclonal gammopathy of undetermined significance.
- Single-cell RNA-sequencing reveals cellular heterogeneity and immune microenvironment characteristics between ocular adnexal mucosa-associated lymphoid lymphoma and IgG4-related ophthalmic disease.
- Similarities and differences of a proliferation-inducing ligand expression in lacrimal gland lesions of patients with IgG4-associated ophthalmic diseases and mucosa-associated lymphoid tissue lymphoma.
- Immunoglobulin G4-related ophthalmic disease with orbital deep hemangioma: A case report.
- Clinicopathologic features and outcomes of bilateral lacrimal gland lesions.
- Clinical Significance of Serum IgG4 in the Diagnosis and Treatment Response of IgG4-Related Disease in Adults of Southwest China: A Retrospective Study.
- Single-cell transcriptome analysis and protein profiling reveal broad immune system activation in IgG4-related disease.
- Malignancies in Chinese patients with immunoglobulin G4-related disease.
- IgG4-Related Disease With Tuberculosis: A Case Report and Retrospective Review of Patients in a Single Center.
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
其他疾病
重症肌无力
Myasthenia gravis2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 16 篇,占 3.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
成都有 4 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下
这家医院参与的开放试验 4
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Myasthenia Gravis Registry in China
- 分期
- 未注明
- 开始
- 2024-02
- 登记号
- NCT06241521
年龄未注明(登记的条件)
牵头:复旦大学附属华山医院;另有 15 家列出的医院为研究中心上海、北京、南昌、天津、广州、徐州、成都、苏州、西安、郑州、重庆、长春、长沙
- 正在招募Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- 分期
- III期
- 开始
- 2024-06
- 登记号
- NCT06463587
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、广州、成都、武汉、沈阳、石家庄、蚌埠、遵义、郑州、长春、长沙
- 正在招募Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
- 分期
- II期
- 开始
- 2022-07
- 登记号
- NCT05067348
年龄 18 岁 至 80 岁(登记的条件)
牵头:空军军医大学唐都医院;另有 5 家列出的医院为研究中心上海、北京、天津、成都、西安、长沙
- 正在招募A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- 分期
- III期
- 开始
- 2021-07
- 登记号
- NCT04951622
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、济南、福州、西安、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文16
- The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis.
- The Role of Exosomes in Central Immune Tolerance and Myasthenia Gravis.
- Clinical study of thyroid eye disease combined with myasthenia gravis.
- Identification of Novel Protein Biomarkers for Myasthenia Gravis by Integrating Human Proteomics with Genetic Instruments.
- The mortality of myasthenia gravis with myocarditis: A single-center retrospective study.
- The Etiology Analysis of Myasthenia Gravis with In-Hospital Mortality in the Neurocritical Care Unit.
- Impact of body mass index on clinical presentation and prognosis in myasthenia gravis.
- Efficacy and Safety of Tacrolimus Therapy in Patients With Juvenile Myasthenia Gravis: A Single-Arm Meta-Analysis.
- The Risk of Exacerbation of Myasthenia Gravis After COVID-19 Omicron Infection.
- Mendelian randomization study revealed a gut microbiota-neuromuscular junction axis in myasthenia gravis.
- Microbiota dysbiosis and myasthenia gravis: Do all roads lead to Rome?
- Association between COVID-19 and myasthenia gravis (MG): A genetic correlation and Mendelian randomization study.
- Unexpected fibrous mediastinitis in a patient with myasthenia gravis - a case report.
- Safety and feasibility of a modularized procedure for trans-subxiphoid robotic extended thymectomy.
- More ectopic thymic tissues resection results in a better outcome for patients with myasthenia gravis†.
- Sexual dysfunction in patients with myasthenia gravis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- Myasthenia Gravis Registry in China
- Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
- A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis
- Study of Telitacicept in Generalized Myasthenia Gravis
- A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
- A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis
其他疾病
烟雾病
Moyamoya disease2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 11 篇,占 3.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
成都有 1 家医院列在烟雾病下全国有 47 家医院列在烟雾病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- 分期
- 未注明
- 开始
- 2026-08
- 登记号
- NCT07894107
年龄 12 岁 至 70 岁(登记的条件)
牵头:首都医科大学附属北京天坛医院;另有 12 家列出的医院为研究中心上海、北京、南昌、成都、杭州、武汉、苏州、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文11
- Drug-Coated Balloon Treatment for LAD CTO in a Young Woman With Moyamoya Disease Guided by Intravascular Imaging.
- Association between angiographic and clinical outcomes after STA-MCA bypass in adult moyamoya disease.
- Long-term outcomes after revascularization surgery for adult moyamoya disease: Protocol for systematic review and meta-analysis.
- Successful perioperative management of a patient undergoing laparoscopic colon surgery with high-risk of cerebral ischemia due to moyamoya disease.
- Ivy Sign: Usefulness in Diagnosis and Prognosis Prediction of Moyamoya Disease.
- Nomogram to Predict Good Collateral Formation After the STA-MCA Bypass Surgery in Adult Patients With Moyamoya Disease.
- Imaging methods for surgical revascularization in patients with moyamoya disease: an updated review.
- Angiographic and Hemodynamic Features in Asymptomatic Hemispheres of Patients With Moyamoya Disease.
- Magnetic Resonance Imaging Markers of Cerebral Small Vessel Disease in Adults with Moyamoya Disease.
- Hemorrhagic stroke caused by moyamoya disease in a patient with obstructive hypertrophic cardiomyopathy.
- Clinical and Hemodynamic Features in Moyamoya Disease with Intracranial Aneurysms.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
胆道闭锁
Biliary atresia2021–2025 年中国大陆作者发表的 214 篇胆道闭锁 PubMed 英文论文中,这家医院牵头了 7 篇,占 3.3%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 2 家医院列在胆道闭锁下全国有 28 家医院列在胆道闭锁下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胆道闭锁开放试验。
这些数字背后的记录
牵头的论文7
- Sequential treatment strategy for biliary atresia: Kasai hepatoportoenterostomy-liver transplantation: a single-center retrospective comparative cohort study.
- Diagnostic performance and prognostic value of elastography in patients with biliary atresia and after hepatic portoenterostomy: protocol for a systematic review and meta-analysis.
- ANKRD1 and SPP1 as diagnostic markers and correlated with immune infiltration in biliary atresia.
- Medium-term outcomes after laparoscopic revision of laparoscopic Kasai portoenterostomy in patients with biliary atresia.
- Laparoscopic Kasai portoenterostomy for cystic biliary atresia: midterm follow-up results of 35 patients.
- The short-term outcome of modified laparoscopic Kasai portoenterostomy for biliary atresia.
- Congenital biliary atresia is correlated with disrupted cell junctions and polarity caused by Cdc42 insufficiency in the liver.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 22 篇,占 8.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 5 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。
这些数字背后的记录
牵头的论文22
- Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study.
- Peripheral T-cell subset activation in NMDAR encephalitis: Insights into pathogenesis and biomarker potential for disease monitoring.
- Long-term maintenance of mycophenolate mofetil in anti-NMDA receptor encephalitis (LEARN): a multicentre, open-label, blinded-endpoint, randomised controlled trial.
- The potential role of tACS in improving cognitive dysfunction associated with anti-NMDAR encephalitis.
- Antibody-secreting cells as a source of NR1-IgGs in N-methyl-D-aspartate receptor-antibody encephalitis.
- Intestinal dysbiosis exacerbates susceptibility to the anti-NMDA receptor encephalitis-like phenotype by changing blood brain barrier permeability and immune homeostasis.
- Cortical atrophy in early-stage patients with anti-NMDA receptor encephalitis: a machine-learning MRI study with various feature extraction.
- Efficacy and safety of different oral prednisone tapering courses in adult anti-NMDAR encephalitis: A multicenter prospective cohort study.
- Blood and CSF findings of cellular immunity in anti-NMDAR encephalitis.
- Genome-Wide Association Study Identifies IFIH1 and HLA-DQB1*05:02 Loci Associated With Anti-NMDAR Encephalitis.
- Single-cell RNA sequencing reveals diverse B cell phenotypes in patients with anti-NMDAR encephalitis.
- Patient characteristics and outcome in patients with anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) encephalitis.
- Long-term seizure outcomes in patients with autoimmune encephalitis: A prospective observational registry study update.
- Efficacy and tolerability of intravenous immunoglobulin versus intravenous methylprednisolone treatment in anti-N-methyl-d-aspartate receptor encephalitis.
- Cytokine/chemokine levels in the CSF and serum of anti-NMDAR encephalitis: A systematic review and meta-analysis.
- Clinical Characteristics of Anti-N-Methyl-d-Aspartate Receptor Encephalitis Overlapping with Demyelinating Diseases: A Review.
- Case Report: Overlapping Syndrome of Anti-NMDAR Encephalitis and MOG Inflammatory Demyelinating Disease in a Patient With Human Herpesviruses 7 Infection.
- Electroconvulsive therapy in a patient with positive anti-NMDA receptor antibodies presenting with isolated psychiatric symptoms: A case report.
- Temporal rank of clinical characteristics and prognosis of anti-N-methyl-d-aspartate receptor encephalitis.
- Disturbance of Gut Bacteria and Metabolites Are Associated with Disease Severity and Predict Outcome of NMDAR Encephalitis: A Prospective Case-Control Study.
- High Dose Steroids as First-Line Treatment Increased the Risk of In-Hospital Infections in Patients With Anti-NMDAR Encephalitis.
- Long-term Functional Outcomes and Relapse of Anti-NMDA Receptor Encephalitis: A Cohort Study in Western China.
早期论文(2016–2020 年)18
- Co-expression of NMDA-receptor subunits NR1, NR2A, and NR2B in dysplastic neurons of teratomas in patients with paraneoplastic NMDA-receptor-encephalitis: a retrospective clinico-pathology study of 159 patients.
- Reply: Gut microbiome alterations in anti-NMDA receptor encephalitis: caveats for result interpretation.
- Risk factors for pneumonia in patients with anti-NMDA receptor encephalitis: A single-center retrospective study.
- Long-term cognitive and neuropsychiatric outcomes in patients with anti-NMDAR encephalitis.
- Alterations in the human gut microbiome in anti-N-methyl-D-aspartate receptor encephalitis.
- Late-onset anti-N-methyl-d-aspartate receptor encephalitis in China.
- Allergy in patients with anti-N-methyl-d-aspartate receptor encephalitis.
- Brain magnetic resonance-imaging findings of anti-N-methyl-D-aspartate receptor encephalitis: a cohort follow-up study in Chinese patients.
- Massive idiopathic spontaneous hemothorax complicating anti-N-methyl-d-aspartate receptor encephalitis: A case report.
- Risk factors for mortality in patients with anti-NMDA receptor encephalitis: Reply to comment on data sparsity.
- Risk factors for mortality in patients with anti-NMDA receptor encephalitis.
- Case report of anti-N-methyl-D-aspartate receptor encephalitis in a middle-aged woman with a long history of major depressive disorder.
- Seizure outcomes in patients with anti-NMDAR encephalitis: A follow-up study.
- Clinical characteristics, treatments, and outcomes of patients with anti-N-methyl-d-aspartate receptor encephalitis: A systematic review of reported cases.
- Suicidality is a common and serious feature of anti-N-methyl-D-aspartate receptor encephalitis.
- Comparisons between Psychiatric Symptoms of Patients with Anti-NMDAR Encephalitis and New-Onset Psychiatric Patients.
- Anti-NMDA receptor encephalitis: clinical characteristics, predictors of outcome and the knowledge gap in southwest China.
- Anti-N-methyl-D-aspartate receptor encephalitis: a common cause of encephalitis in the intensive care unit.
其他疾病
大动脉炎
Takayasu arteritis2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 3 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。
这些数字背后的记录
牵头的论文3
早期论文(2016–2020 年)6
- Restenosis of Bilateral Aorta-Renal Saphenous Vein Grafts after the Surgical Repair of Takayasu Arteritis-induced Bilateral Renal Arteries Stenosis: Case Report.
- Interventional therapy for Takayasu arteritis with pulmonary artery and pulmonary vein stenosis.
- Risk of rupture of an aortorenal vein graft aneurysm after the surgical repair of Takayasu arteritis-induced right renal artery stenosis: A case report and a literature review.
- Aneurysmal Degeneration of an Aortorenal Bypass for Takayasu Renal Artery Stenosis: A Novel Endovascular Intervention.
- A Case of Takayasu Arteritis With the Ostium of Left Main Coronary Artery Obstructed by Prolapsed Thickened Ascending Aortic Intima.
- Treatment of severe hypertension in a 14-year-old child: Successful blood pressure control with additive administration of captopril, an angiotensin-converting enzyme inhibitor, in a patient with bilateral renovascular hypertension.
其他疾病
肝包虫病
Hepatic echinococcosis2021–2025 年中国大陆作者发表的 152 篇肝包虫病 PubMed 英文论文中,这家医院牵头了 14 篇,占 9.2%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 5 家医院列在肝包虫病下全国有 49 家医院列在肝包虫病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。
这些数字背后的记录
牵头的论文14
- High PD-1 and CTLA-4 expression correlates with host immune suppression in patients and a mouse model infected with Echinococcus multilocularis.
- Epidemiology and Clinical Characteristics of Cerebral Alveolar Echinococcosis in the Tibetan Region of Sichuan, China.
- Pictorial review of hepatic echinococcosis: Ultrasound imaging and differential diagnosis.
- Two-step resection procedure for advanced hepatic alveolar echinococcosis: First case-series report.
- Lung and brain recurrence after liver transplantation for advanced alveolar echinococcosis: A case report.
- Successful laparoscopic anatomical resection of segments V and VIII for hepatic alveolar echinococcosis with diaphragmatic involvement: A case report.
- Can contrast-enhanced ultrasound differentiate the type of hepatic echinococcosis: cystic echinococcosis or alveolar echinococcosis?
- Evaluating the Benefits and Risks of Ex Vivo Liver Resection and Autotransplantation in Treating Hepatic End-stage Alveolar Echinococcosis.
- Two-stage hepatectomy combined with middle hepatic vein reconstruction in a patient with complicated hepatic alveolar echinococcosis.
- Severe hypernatremia in children after surgical resection of hepatic echinococcosis: a rare and potentially fatal complication.
- Application of ex vivo liver resection and autotransplantation in treating Budd-Chiari syndrome secondary to end-stage hepatic alveolar echinococcosis: A case series.
- Treatment of retroperitoneal echinococcosis: the experience of a single center.
- Triphase contrast-enhanced CT to evaluate indications for autologous liver transplantation in patients with end-stage hepatic alveolar echinococcosis.
- Hydatid Pulmonary Embolism: A Case Report and Literature Review.
中文论文(未计入)2
早期论文(2016–2020 年)22
- Another case of hepatic alveolar echinococcosis?
- Individualized biliary reconstruction techniques in autotransplantation for end-stage hepatic alveolar echinococcosis.
- Epidemiological characteristics of hepatic echinococcosis, concurrent cerebral echinococcosis, and pulmonary echinococcosis in Ganzi County, Sichuan Province, China.
- Preoperative nutritional evaluation of patients with hepatic alveolar echinococcosis.
- Outcomes of different surgical resection techniques for end-stage hepatic alveolar echinococcosis with inferior vena cava invasion.
- Ex vivo liver resection and autotransplantation versus allotransplantation for end-stage hepatic alveolar echinococcosis.
- Remnant Liver-to-Standard Liver Volume Ratio Below 40% is Safe in Ex Vivo Liver Resection and Autotransplantation.
- Transhepatic-intrahepatic branches of the portal vein catheterization for ex vivo liver resection and autotransplantation: Two case reports of novel approach to perfuse the liver.
- Doughnut sign of hepatic alveolar echinococcosis on FDG PET/CT: Clinical case report.
- The role of contrast-enhanced ultrasound in the diagnosis of hepatic alveolar echinococcosis.
- Surgical approaches for definitive treatment of hepatic alveolar echinococcosis: results of a survey in 178 patients.
- Vascular infiltration-based surgical planning in treating end-stage hepatic alveolar echinococcosis with ex vivo liver resection and autotransplantation.
- Residual cavity hydrops initially misdiagnosed as recurrent hepatic echinococcosis.
- Novel techniques and preliminary results of ex vivo liver resection and autotransplantation for end-stage hepatic alveolar echinococcosis: A study of 31 cases.
- The choose of different surgical therapies of hepatic alveolar echinococcosis: A single-center retrospective case-control study.
- Ultrasonographic findings of small lesion of hepatic alveolar echinococcosis.
- Risk factors and a simple model for predicting bile leakage after radical hepatectomy in patients with hepatic alveolar echinococcosis.
- The association of hypernatremia and hypertonic saline irrigation in hepatic hydatid cysts: A case report and retrospective study.
- Two-stage hepatectomy for multiple giant alveolar echinococcosis.
- Hepatectomy for patients with alveolar echinococcosis: Long-term follow-up observations of 144 cases.
- Multiorgan resection with inferior vena cava reconstruction for hepatic alveolar echinococcosis: A case report and literature review.
- Hepatic Vein Injuries During Laparoscopic Hepatectomy.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 31 篇,占 3.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
成都有 16 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- 分期
- III期
- 开始
- 2026-09
- 登记号
- NCT07687459
年龄 40 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文31
- Biomimetic Topological Micropattern Arrays Regulate the Heterogeneity of Cellular Fates in Lung Fibroblasts between Fibrosis and Invasion.
- Discovery of novel capsaicin analogs as TRPV1 inhibitors for the treatment of idiopathic pulmonary fibrosis.
- The Ketone Body β-Hydroxybutyrate Mitigates the Ferroptosis of Alveolar Epithelial Cells Type II in Bleomycin-Induced Pulmonary Fibrosis.
- CAR-engineered cytolytic Tregs reverse pulmonary fibrosis and remodel the fibrotic niche with limited CRS.
- Efficacy and safety of antifibrotic drugs for interstitial lung diseases other than IPF: A systematic review, meta-analysis and trial sequential analysis.
- Pathogenesis and current status of the treatment of lung cancer associated with idiopathic pulmonary fibrosis.
- The value of macrolides in the adjuvant treatment of pulmonary fibrosis: maybe a panacea.
- Tetrahedral Framework Nucleic Acids Delivery of Pirfenidone for Anti-Inflammatory and Antioxidative Effects to Treat Idiopathic Pulmonary Fibrosis.
- INTEGRIS-IPF: A New Hope for Tomorrow.
- Acute exacerbation of idiopathic pulmonary fibrosis disease: a diagnosis model in China.
- Buyang Huanwu decoction ameliorates bleomycin-induced pulmonary fibrosis in rats by attenuating the apoptosis of alveolar type II epithelial cells mediated by endoplasmic reticulum stress.
- Authors' Reply to Letter to the Editor Regarding the Article "Genetic Association of Circulating Adipokines with Risk of Idiopathic Pulmonary Fibrosis: a Two-Sample Mendelian Randomization Study".
- Identifying potential drug targets for idiopathic pulmonary fibrosis: a mendelian randomization study based on the druggable genes.
- Diagnostic and prognostic value of secreted phosphoprotein 1 for idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
- Discovery of indoline-based derivatives as effective ROCK2 inhibitors for the potential new treatment of idiopathic pulmonary fibrosis.
- AAV9-Tspyl2 gene therapy retards bleomycin-induced pulmonary fibrosis by modulating downstream TGF-β signaling in mice.
- Emerging opportunities to treat idiopathic pulmonary fibrosis: Design, discovery, and optimizations of small-molecule drugs targeting fibrogenic pathways.
- Discovery of the novel Benzo[b]thiophene 1,1-dioxide derivatives as a potent STAT3 inhibitor against idiopathic pulmonary fibrosis.
- Design, synthesis and biological evaluation of novel diarylacylhydrazones derivatives for the efficient treatment of idiopathic pulmonary fibrosis.
- Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP-198, a novel, selective Autotaxin inhibitor, in healthy subjects: A phase I randomized placebo-controlled trial.
- Diabetic endothelial microangiopathy and pulmonary dysfunction.
- Decreased Th1 Cells and Increased Th2 Cells in Peripheral Blood Are Associated with Idiopathic Inflammatory Myopathies Patients with Interstitial Lung Disease.
- Niclosamide-loaded nanoparticles (Ncl-NPs) reverse pulmonary fibrosis in vivo and in vitro.
- Genetic Association of Circulating Adipokines with Risk of Idiopathic Pulmonary Fibrosis: A Two-Sample Mendelian Randomization Study.
- Efficacy and safety of antifibrotic agents in the treatment of CTD-ILD and RA-ILD: A systematic review and meta-analysis.
- Noncanonical JAK1/STAT3 interactions with TGF-β modulate myofibroblast transdifferentiation and fibrosis.
- Role of Circular RNAs in Pulmonary Fibrosis.
- Nifuroxazide ameliorates pulmonary fibrosis by blocking myofibroblast genesis: a drug repurposing study.
- Matrix metalloproteinases inhibitors in idiopathic pulmonary fibrosis: Medicinal chemistry perspectives.
- Can YKL-40 be used as a biomarker for interstitial lung disease?: A systematic review and meta-analysis.
- Impact of concomitant idiopathic pulmonary fibrosis on prognosis in lung cancer patients: A meta-analysis.
中文论文(未计入)1
早期论文(2016–2020 年)5
- Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway.
- Diabetes Mellitus Contributes to Idiopathic Pulmonary Fibrosis: A Review From Clinical Appearance to Possible Pathogenesis.
- Mitochondrial dysfunction and chronic lung disease.
- In Silico Detection and Characterization of microRNAs and Their Target Genes in microRNA Microarray Datasets from Patients with Systemic Sclerosis-Interstitial Lung Disease.
- Identification of novel inhibitors of DDR1 against idiopathic pulmonary fibrosis by integrative transcriptome meta-analysis, computational and experimental screening.
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
- A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
其他疾病
肺淋巴管平滑肌瘤病
Lymphangioleiomyomatosis2021–2025 年中国大陆作者发表的 45 篇肺淋巴管平滑肌瘤病 PubMed 英文论文中,这家医院牵头了 2 篇,占 4.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 2 家医院列在肺淋巴管平滑肌瘤病下全国有 28 家医院列在肺淋巴管平滑肌瘤病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肺淋巴管平滑肌瘤病开放试验。
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 60 篇,占 7.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
成都有 8 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
- 分期
- I期
- 开始
- 2024-12
- 登记号
- NCT06556394
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、成都、杭州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文60
- Untargeted metabolomics based on LC-MS and GC-MS reveal metabolic reprogramming and putative biomarkers in amyotrophic lateral sclerosis.
- Loss of Y chromosome and its implications in male amyotrophic lateral sclerosis: insights from the UK Biobank.
- Genetically Predict Diet-derived Antioxidants and Risk of Neurodegenerative Diseases Among Individuals of European Descent: A Mendelian Randomization Study.
- Mutation Screening of ATXN1, ATXN2, and ATXN3 in Amyotrophic Lateral Sclerosis.
- Association between Psychiatric Disorders and Amyotrophic Lateral Sclerosis: A Prospective Cohort Study from the UK Biobank.
- Association between metabolic syndrome, its individual components and progression of amyotrophic lateral sclerosis.
- Association of creatinine level with neurodegenerative disorders: a prospective cohort study and Mendelian randomization analysis.
- Viral infections and the risk of neurodegenerative diseases: a comprehensive meta-analysis and systematic review.
- Association between sleep and ALS-FTSD: A Prospective Cohort Study based on 396,918 UK biobank participants.
- Peripheral immunity relate to disease progression and prognosis in amyotrophic lateral sclerosis.
- The C9orf72-SMCR8 complex suppresses primary ciliogenesis as a RAB8A GAP.
- TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro.
- Causal relationship between PCSK9 inhibitor and common neurodegenerative diseases: A drug target Mendelian randomization study.
- Differential cortical gray matter changes in early- and late-onset patients with amyotrophic lateral sclerosis.
- Genotype-phenotype correlation of SQSTM1 variants in patients with amyotrophic lateral sclerosis.
- Amyotrophic lateral sclerosis patients with various gene mutations show diverse motor phenotypes and survival in China.
- Clinical and genetic characteristics of ALS patients with variants in genes regulating DNA methylation.
- Genome-wide DNA methylation analysis related to ALS patient progression and survival.
- The Long Non-Coding RNA NR3C2-8:1 Promotes p53-Mediated Apoptosis through the miR-129-5p/USP10 Axis in Amyotrophic Lateral Sclerosis.
- Discovery and Exploration of Lipid-Modifying Drug Targets for ALS by Mendelian Randomization.
- Lnc-HIBADH-4 Regulates Autophagy-Lysosome Pathway in Amyotrophic Lateral Sclerosis by Targeting Cathepsin D.
- Rare DNAJC7 Variants May Play a Minor Role in Chinese Patients with ALS.
- Abnormal Brain Protein Abundance and Cross-tissue mRNA Expression in Amyotrophic Lateral Sclerosis.
- Total physical activity, plant-based diet and neurodegenerative diseases: A prospective cohort study of the UK biobank.
- Downregulation of Lnc-ABCA12-3 modulates UBQLN1 expression and protein homeostasis pathways in amyotrophic lateral sclerosis.
- BL-918, a small-molecule activator of ULK1, induces cytoprotective autophagy for amyotrophic lateral sclerosis therapy.
- Association between vascular risk factors and cognitive impairment in amyotrophic lateral sclerosis: a case-control study.
- Genetic Modifiers of Age at Onset for Amyotrophic Lateral Sclerosis: A Genome-Wide Association Study.
- TBK1 variants in Chinese patients with amyotrophic lateral sclerosis: Genetic analysis and clinical features.
- Multisite chronic pain and the risk of autoimmune diseases: A Mendelian randomization study.
- Mutation screening of SPTLC1 and SPTLC2 in amyotrophic lateral sclerosis.
- Identifying novel genes for amyotrophic lateral sclerosis by integrating human brain proteomes with genome-wide association data.
- Physical activity as risk factor in amyotrophic lateral sclerosis: a systematic review and meta-analysis.
- Genetic and Phenotypic Spectrum of Amyotrophic Lateral Sclerosis Patients with CCNF Variants from a Large Chinese Cohort.
- Genome-wide analyses identify NEAT1 as genetic modifier of age at onset of amyotrophic lateral sclerosis.
- Genetic and clinical characteristics of ALS patients with NEK1 gene variants.
- ALS-linked C9orf72-SMCR8 complex is a negative regulator of primary ciliogenesis.
- Venous blood parameters in determination of respiratory impairment in amyotrophic lateral sclerosis.
- Sleep in amyotrophic lateral sclerosis: A systematic review and meta-analysis of polysomnographic findings.
- A case of juvenile-onset amyotrophic lateral sclerosis with a de novo frameshift FUS gene mutation presenting with bilateral abducens palsy.
- Genetic factors for survival in amyotrophic lateral sclerosis: an integrated approach combining a systematic review, pairwise and network meta-analysis.
- Spatial-temporal pattern of propagation in amyotrophic lateral sclerosis and effect on survival: A cohort study.
- A Prediction Model for Peak Expiratory Flow Derived From Venous Blood Biomarkers and Clinical Factors in Amyotrophic Lateral Sclerosis.
- Lack of association of TP73 rare variants with amyotrophic lateral sclerosis in a Chinese cohort.
- Role of genetics in amyotrophic lateral sclerosis: a large cohort study in Chinese mainland population.
- The role of Th17 cells/IL-17A in AD, PD, ALS and the strategic therapy targeting on IL-17A.
- The expression discrepancy and characteristics of long non-coding RNAs in peripheral blood leukocytes from amyotrophic lateral sclerosis patients.
- Mutation Screening of TFG in α-Synucleinopathy and Amyotrophic Lateral Sclerosis.
- Genetic analysis of and clinical characteristics associated with ANXA11 variants in a Chinese cohort with amyotrophic lateral sclerosis.
- The progress in C9orf72 research: ALS/FTD pathogenesis, functions and structure.
- Genome-wide genetic links between amyotrophic lateral sclerosis and autoimmune diseases.
- Early weight instability is associated with cognitive decline and poor survival in amyotrophic lateral sclerosis.
- Predictors of survival in patients with amyotrophic lateral sclerosis: A large meta-analysis.
- Health-related quality of life in amyotrophic lateral sclerosis using EQ-5D-5L.
- Risk factors for cognitive impairment in amyotrophic lateral sclerosis: a systematic review and meta-analysis.
- The Evaluation of Pain with Nociceptive and Neuropathic Characteristics from Three Different Perspectives in Amyotrophic Lateral Sclerosis Patients: A Case Controlled Observational Study in Southwestern China.
- Shared genetic links between amyotrophic lateral sclerosis and obesity-related traits: a genome-wide association study.
- Mutation screening and burden analysis of GLT8D1 in Chinese patients with amyotrophic lateral sclerosis.
- Disruption of the white matter structural network and its correlation with baseline progression rate in patients with sporadic amyotrophic lateral sclerosis.
- Aberrations of biochemical indicators in amyotrophic lateral sclerosis: a systematic review and meta-analysis.
早期论文(2016–2020 年)38
- Effects of Exercise in Patients With Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.
- Serum creatinine levels in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis.
- The C9orf72-SMCR8-WDR41 complex is a GAP for small GTPases.
- LanCL1 promotes motor neuron survival and extends the lifespan of amyotrophic lateral sclerosis mice.
- MicroRNA-183-5p is stress-inducible and protects neurons against cell death in amyotrophic lateral sclerosis.
- Causal Association of Leukocytes Count and Amyotrophic Lateral Sclerosis: a Mendelian Randomization Study.
- Cryo-EM structure of C9ORF72-SMCR8-WDR41 reveals the role as a GAP for Rab8a and Rab11a.
- Patterns of brain regional functional coherence in cognitive impaired ALS.
- Systematic review of the prognostic role of body mass index in amyotrophic lateral sclerosis.
- Clinical disease stage related changes of serological factors in amyotrophic lateral sclerosis.
- Neurophysiological index is associated with the survival of patients with amyotrophic lateral sclerosis.
- Mutation screening of the KIF5A gene in Chinese patients with amyotrophic lateral sclerosis.
- Unique characteristics of the genetics epidemiology of amyotrophic lateral sclerosis in China.
- An association study between SCFD1 rs10139154 variant and amyotrophic lateral sclerosis in a Chinese cohort.
- Clinical and prognostic features of ALS/MND in different phenotypes-data from a hospital-based registry.
- Determining the Effect of the HNMT, STK39, and NMD3 Polymorphisms on the Incidence of Parkinson's Disease, Amyotrophic Lateral Sclerosis, and Multiple System Atrophy in Chinese Populations.
- Altered white matter microarchitecture in amyotrophic lateral sclerosis: A voxel-based meta-analysis of diffusion tensor imaging.
- Mutation screening of the TIA1 gene in Chinese patients with amyotrophic lateral sclerosis/frontotemporal dementia.
- Meta-analysis of the association between ZNF512B polymorphism rs2275294 and risk of amyotrophic lateral sclerosis.
- The relationship between four GWAS-identified loci in Alzheimer's disease and the risk of Parkinson's disease, amyotrophic lateral sclerosis, and multiple system atrophy.
- Association analysis of SNP rs11868035 in SREBF1 with sporadic Parkinson's disease, sporadic amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population.
- Absence of association of the Ala58Val (rs17571) CTSD gene variant with Parkinson's disease or amyotrophic lateral sclerosis in a Han Chinese population.
- White matter volume loss in amyotrophic lateral sclerosis: A meta-analysis of voxel-based morphometry studies.
- Why might ALS have negative effects on patients with out-of-hospital cardiac arrest?
- [Roles of exosomes in Parkinson's disease and amyotrophic lateral sclerosis].
- Patients' self-perceived burden, caregivers' burden and quality of life for amyotrophic lateral sclerosis patients: a cross-sectional study.
- Association analysis of polymorphisms in VMAT2 and TMEM106B genes for Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy.
- HLA-DRA/HLA-DRB5 polymorphism affects risk of sporadic ALS and survival in a southwest Chinese cohort.
- Mutation Screening of the CHCHD10 Gene in Chinese Patients with Amyotrophic Lateral Sclerosis.
- Blood hemoglobin A1c levels and amyotrophic lateral sclerosis survival.
- Analysis of SOD1 mutations in a Chinese population with amyotrophic lateral sclerosis: a case-control study and literature review.
- Associations between neuropsychiatric symptoms and cognition in Chinese patients with amyotrophic lateral sclerosis.
- Assessment of a multiple biomarker panel for diagnosis of amyotrophic lateral sclerosis.
- Mutational analysis of CHCHD2 in Chinese patients with multiple system atrophy and amyotrophic lateral sclerosis.
- SLC1A2 rs3794087 are associated with susceptibility to Parkinson's disease, but not essential tremor, amyotrophic lateral sclerosis or multiple system atrophy in a Chinese population.
- Large C9orf72 repeat expansions are seen in Chinese patients with sporadic amyotrophic lateral sclerosis.
- Association between depression and survival in Chinese amyotrophic lateral sclerosis patients.
- No association of GPNMB rs156429 polymorphism with Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy in Chinese population.
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
- An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis
其他疾病
脊髓性肌萎缩症
Spinal muscular atrophy2021–2025 年中国大陆作者发表的 55 篇脊髓性肌萎缩症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 3 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊髓性肌萎缩症开放试验。
其他疾病
法布雷病
Fabry disease2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 5 篇,占 6.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
成都有 2 家医院列在法布雷病下全国有 85 家医院列在法布雷病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- 分期
- 未注明
- 开始
- 2025-11
- 登记号
- NCT07187440
年龄 7 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 18 家列出的医院为研究中心北京、南京、合肥、哈尔滨、天津、太原、成都、杭州、汕头、深圳、石家庄、福州、苏州、西安
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文5
- Screening for Fabry disease in patients with hypertrophic cardiomyopathy using cardiac magnetic resonance imaging.
- Left Ventricular Hemodynamic Forces Changes in Fabry Disease: A Cardiac Magnetic Resonance Study.
- GLA deficiency causes cardiac hypertrophy via enhanced autophagy.
- Identification of c.146G > A mutation in a Fabry patient and its correction by customized Cas9 base editors in vitro.
- Fabry Disease with Genetic Variants of Unknown Significance and Concomitant Immunoglobulin A Nephropathy.
早期论文(2016–2020 年)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
其他疾病
庞贝病
Pompe disease2021–2025 年中国大陆作者发表的 30 篇庞贝病 PubMed 英文论文中,这家医院牵头了 2 篇,占 6.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 2 家医院列在庞贝病下全国有 30 家医院列在庞贝病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的庞贝病开放试验。
其他疾病
杜氏肌营养不良
Duchenne muscular dystrophy2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 4 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。
这些数字背后的记录
牵头的论文2
早期论文(2016–2020 年)2
其他疾病
白塞病
Behçet disease2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 6 篇,占 2.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 5 家医院列在白塞病下全国有 149 家医院列在白塞病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。
这些数字背后的记录
牵头的论文6
- Surgery for pseudoaneurysm following the Bentall procedure in a patient with Behçet's disease: A case report.
- Life-Threatening Involvement of Bilateral Pulmonary Arteries in Behçet Disease on FDG PET.
- 'Caterpillar-like' pseudoaneurysms in Behçet's disease.
- Gastrointestinal Behçet Disease Secondary to Myelodysplastic Syndrome.
- Chronic active Epstein-Barr virus infection manifest as extensive mucocutaneous ulceration mimicking Behçet's disease.
- Prosthetic valve detachment complicated with intervalvular fibrous body destruction in Behcet's disease: a case report.
早期论文(2016–2020 年)5
- A right ventricular mass in a young man with Behçet's disease: A case report.
- Behcet's disease involved the root of aorta in the treatment with modified Bentall procedure: a case report.
- Vocal cord involvement and hoarseness in a patient with Behcets disease: A rare case report.
- Sudden unilateral vision loss in an adult with Behcet disease: A case report.
- Successful mesenchymal stem cell treatment of leg ulcers complicated by Behcet disease: A case report and literature review.
其他疾病
Alport 综合征
Alport syndrome2021–2025 年中国大陆作者发表的 58 篇Alport 综合征 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 4 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 34 篇,占 4.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
成都有 9 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- 分期
- III期
- 开始
- 2025-07
- 登记号
- NCT06963827
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、包头、北京、南京、南昌、南通、厦门、宁波、广州、成都、无锡、杭州、济南、深圳、珠海、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文34
- 2bRAD-M reveals circulating microbiome in chronic antibody-mediated rejection (CAMR) and IgA nephropathy (IgAN) after kidney transplantation.
- Particulate matter exposure and end-stage renal disease risk in IgA nephropathy.
- High systemic inflammatory response index (SIRI) is an independent risk factor for poor outcome in IgA nephropathy patients.
- Risk Stratification in Immunoglobulin A Nephropathy Using Network Biomarkers: Development and Validation Study.
- Association between different proportions of crescents and adverse renal outcomes in immunoglobulin a nephropathy: a systematic review and meta-analysis.
- Efficacy and safety of telitacicept in IgA nephropathy: a real-world study.
- Personalized decision support system for tailoring IgA nephropathy treatment strategies.
- Demographic distribution analysis of different glomerular diseases in Southwest China from 2008 to 2022.
- Fabry Disease with Genetic Variants of Unknown Significance and Concomitant Immunoglobulin A Nephropathy.
- Combined Effects of the Serum IgA/C3 Ratio and Glomerular C3 Staining on the Renal Outcome in Adult Immunoglobulin A Nephropathy.
- The clinical and pathological evaluation of patients with immunoglobulin A nephropathy by diffusion tensor imaging and intravoxel incoherent motion diffusion-weighted imaging.
- Nephrotic proteinuria and hematuria with newly diagnosed IgA nephropathy after liver transplant: A case report.
- Altered serum metabolic profile in patients with IgA nephropathy.
- Association of obesity with the development of end stage renal disease in IgA nephropathy patients.
- Risk factors and outcomes of IgA nephropathy recurrence after kidney transplantation: a systematic review and meta-analysis.
- Roles of mesangial C3 and C1q deposition in the clinical manifestations and prognosis of IgAN.
- Uric acid-based ratios for predicting renal failure in Chinese IgA nephropathy patients.
- Characterization of site-specific N-glycosylation signatures of isolated uromodulin from human urine.
- IgA Nephropathy in a Patient With Metastatic Carcinoma of Unknown Primary: Findings on 18F-FDG PET/MRI.
- Prognostic Value of Triglyceride to High-Density Lipoprotein Cholesterol Ratio (TG/HDL-C) in IgA Nephropathy Patients.
- Platelet-to-Albumin Ratio: A Novel IgA Nephropathy Prognosis Predictor.
- Association of genetic polymorphisms in IL-23R and IL-17A with the susceptibility to IgA nephropathy in a Chinese Han population.
- Prognostic value of the albumin-to-fibrinogen ratio (AFR) in IgA nephropathy patients.
- The Ratio of CD226 and TIGIT Expression in Tfh and PD-1+ICOS+Tfh Cells Are Potential Biomarkers for Chronic Antibody-Mediated Rejection in Kidney Transplantation.
- Probiotics ameliorate IgA nephropathy by improving gut dysbiosis and blunting NLRP3 signaling.
- Clinicopathological characteristics and risk factors in elderly patients with biopsy-proven IgA nephropathy.
- Cigarette smoking may accelerate the progression of IgA nephropathy.
- Mesangial IgM deposition predicts renal outcome in patients with IgA nephropathy: a multicenter, observational study.
- Epigenome-wide association study and network analysis for IgA Nephropathy from CD19+ B-cell in Chinese Population.
- High Neutrophil-To-Lymphocyte Ratio Is an Independent Risk Factor for End Stage Renal Diseases in IgA Nephropathy.
- Lower serum bilirubin is associated with poor renal outcome in IgA nephropathy patients.
- Sex disparities in IgA nephropathy: a retrospective study in Chinese patients.
- Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria.
- A multicenter, prospective, observational study to determine association of mesangial C1q deposition with renal outcomes in IgA nephropathy.
早期论文(2016–2020 年)13
- Modifications of gut microbiota are associated with the severity of IgA nephropathy in the Chinese population.
- Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria.
- Glomerular C4 deposition and glomerulosclerosis predict worse renal outcomes in Chinese patients with IgA nephropathy.
- The efficacy and safety of immunosuppressive therapies in the treatment of IgA nephropathy: A network meta-analysis.
- [Effect of serum IgA/C3 and glomerular C3 staining on clinical prognosis in patients with IgA nephropathy].
- Clinical and pathological features of immunoglobulin A nephropathy patients with nephrotic syndrome.
- IgA1 deposition may induce NLRP3 expression and macrophage transdifferentiation of podocyte in IgA nephropathy.
- Crescents and Global Glomerulosclerosis in Chinese IgA Nephropathy Patients: A Five-Year Follow-Up.
- Combined Immunosuppressive Treatment May Improve Short-Term Renal Outcomes in Chinese Patients with Advanced IgA Nephropathy.
- Interleukin 18 -607 A/C Gene Polymorphism is Associated With Susceptibility to IgA Nephropathy in a Chinese Han Population.
- MicroRNA-155-induced T lymphocyte subgroup drifting in IgA nephropathy.
- The effect of calcineurin inhibitors in the treatment of IgA nephropathy: A systematic review and meta-analysis (PRISMA).
- Bacterial IgA protease-mediated degradation of agIgA1 and agIgA1 immune complexes as a potential therapy for IgA Nephropathy.
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)
- TESTING -ON Post-Trial ObservatioNal Cohort Study
- Atrasentan in Patients With IgA Nephropathy
- Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
其他疾病
戈谢病
Gaucher disease2021–2025 年没有牵头戈谢病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 1 家医院列在戈谢病下全国有 41 家医院列在戈谢病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的戈谢病开放试验。
这些数字背后的记录
早期论文(2016–2020 年)1
其他疾病
成骨不全症
Osteogenesis imperfecta2021–2025 年没有牵头成骨不全症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 2 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 11 篇,占 3.7%。
- 牵头的开放试验
- 0
- 正在或即将招募
成都有 4 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- 分期
- III期
- 开始
- 2025-12
- 登记号
- NCT07282353
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 35 家列出的医院为研究中心Baoji、上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛
- 正在招募Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- 分期
- III期
- 开始
- 2023-09
- 登记号
- NCT06051617
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文11
- Association of sarcopenia assessed by CT/MRI with treatment response and clinical outcomes in noncirrhotic primary biliary cholangitis patients.
- Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis.
- Noninvasive prediction of insufficient biochemical response after ursodeoxycholic acid treatment in patients with primary biliary cholangitis based on pretreatment nonenhanced MRI.
- Mycophenolate mofetil for the induction of remission in primary biliary cholangitis with predominant features of autoimmune hepatitis.
- Multi-omics approaches for drug-response characterization in primary biliary cholangitis and autoimmune hepatitis variant syndrome.
- Factors and cytokine signatures associated with the response to therapy in patients with primary biliary cholangitis-autoimmune hepatitis overlap syndrome: a real-world study.
- Hematologic traits and primary biliary cholangitis: a Mendelian randomization study.
- Causal associations between inflammatory bowel disease and primary biliary cholangitis: a two-sample bidirectional Mendelian randomization study.
- Clinical utility of two-dimensional shear-wave elastography in monitoring disease course in autoimmune hepatitis-primary biliary cholangitis overlap syndrome.
- Ursodeoxycholic Acid at 18-22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis.
- Worse Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients with Autoimmune Hepatitis Features.
早期论文(2016–2020 年)9
- Primary biliary cholangitis with autoimmune hepatitis features: What's the appropriate criteria to evaluate the treatment-response?
- Concomitant systemic lupus erythematosus might have a negative impact on the biochemical responses to treatment in patients with primary biliary cholangitis.
- Assessment of biopsy proven liver fibrosis by two-dimensional shear wave elastography in patients with primary biliary cholangitis.
- Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis.
- Severe anemia caused by hereditary hemorrhagic telangiectasia in a patient with Sjögren's syndrome and primary biliary cirrhosis.
- Past hepatitis B virus infection was not associated with poorer response or the UK-PBC risk score in ursodeoxycholic acid-treated patients with primary biliary cirrhosis.
- Genetic association of E26 transformation specific sequence 1 polymorphisms with the susceptibility of primary biliary cholangitis in China.
- Efficacy and Safety of Immunosuppressive Therapy for PBC-AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study.
- Underestimated Male Prevalence of Primary Biliary Cholangitis in China: Results of a 16-yr cohort study involving 769 patients.
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
- Ursodeoxycholic Acid Combined With Total Glucosides of Paeony in the Treatment of PBC With AIH Features 1
- Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy
- Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II
- A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis
- The Comparison About the Response of Ursodeoxycholic Acid in Primary Biliary Cholangitis Only and Primary Biliary Cholangitis With High Immune Globulin G or Aminotransferase at West China Hospital
- A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome
- Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
- Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome
- A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
- Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis
其他疾病
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 3 篇,占 3.0%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 2 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。
这些数字背后的记录
牵头的论文3
- Apremilast as a novel therapeutic option for psoriasis coexisting primary sclerosing cholangitis and ulcerative colitis: A case report.
- Causality of immune cells on primary sclerosing cholangitis: a bidirectional two-sample Mendelian randomization study.
- Liver transplantation in a child with liver cirrhosis caused by langerhans cell histiocytosis: a case report.
早期论文(2016–2020 年)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
先天性膈疝
Congenital diaphragmatic hernia2021–2025 年中国大陆作者发表的 60 篇先天性膈疝 PubMed 英文论文中,这家医院牵头了 5 篇,占 8.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 4 家医院列在先天性膈疝下全国有 46 家医院列在先天性膈疝下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性膈疝开放试验。
这些数字背后的记录
牵头的论文5
- Global birth prevalence of major congenital anomalies: a systematic review and meta-analysis.
- Fetal endoscopic tracheal occlusion for congenital diaphragmatic hernia: systematic review and meta-analysis.
- A rare Bochdalek hernia in an adult: a case report.
- Emergency Management of Acute Late-Presenting Congenital Diaphragmatic Hernia in Infants and Children.
- Do B-type natriuretic peptide levels accurately predict outcome in infants with congenital diaphragmatic hernia?
早期论文(2016–2020 年)4
- Another type of diaphragmatic hernia to remember: parahiatal hernia.
- Thoracoscopic Treatment of Late-Presenting Congenital Diaphragmatic Hernia in Infants and Children.
- Minimally invasive surgery for congenital diaphragmatic hernia: a meta-analysis.
- [OBSERVATION OF EFFECTIVENESS OF THORACOSCOPIC SURGERY FOR LATEPRESENTING CONGENITAL DIAPHRAGMATIC HERNIA].
其他疾病
先天性巨结肠
Hirschsprung disease2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 2 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。
其他疾病
遗传性大疱性表皮松解症
Inherited epidermolysis bullosa2021–2025 年中国大陆作者发表的 56 篇遗传性大疱性表皮松解症 PubMed 英文论文中,这家医院牵头了 4 篇,占 7.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 1 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。
这些数字背后的记录
牵头的论文4
- Novel compound heterozygous mutations of the COL7A1 gene in a Chinese patient with recessive dystrophic epidermolysis bullosa pruriginosa and digestive symptoms successfully treated with tofacitinib.
- A heterozygous mutation in ITGB4 causing a mild phenotype of junctional epidermolysis bullosa.
- Exon 8 deletion of KRT5 in epidermolysis bullosa simplex with mottled pigmentation: A case report.
- Identification of novel compound heterozygous ITGB4 mutations in a Chinese woman with junctional epidermolysis bullosa without pylori atresia but profound urinary symptoms: A case report and review of the literature.
其他疾病
遗传性血管性水肿
Hereditary angioedema2021–2025 年中国大陆作者发表的 32 篇遗传性血管性水肿 PubMed 英文论文中,这家医院牵头了 2 篇,占 6.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 2 家医院列在遗传性血管性水肿下全国有 30 家医院列在遗传性血管性水肿下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性血管性水肿开放试验。
这些数字背后的记录
牵头的论文2
其他疾病
家族性腺瘤性息肉病
Familial adenomatous polyposis2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 2 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。
联系这家医院
出示给工作人员或司机的院名卡
四川大学华西医院
West China Hospital
成都
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR
West China Hospital of Sichuan University; Sichuan University West China Hospital; West China Hospital Sichuan University; West China Hospital Sichuan University Chengdu Sichuan China; Digestive Endoscopic Center of West China Hospital; Biomedical Big Data Center of West China Hospital; Operation Room of West China Hospital; Chengdu Shang Jin Nan Fu Hospital West China Hospital